<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-10451R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0006412</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology</subject><subject>Oncology</subject><subject>Immunology/Immune Response</subject><subject>Physiology/Immune Response</subject><subject>Oncology/Gynecological Cancers</subject><subject>Pathology/Immunology</subject><subject>Women's Health/Gynecological Cancers</subject></subj-group></article-categories><title-group><article-title>Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors</article-title><alt-title alt-title-type="running-head">Immune Cells in Ovarian Cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Milne</surname><given-names>Katy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>K&#x000f6;bel</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kalloger</surname><given-names>Steven E.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barnes</surname><given-names>Rebecca O.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Dongxia</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gilks</surname><given-names>C. Blake</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Watson</surname><given-names>Peter H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nelson</surname><given-names>Brad H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia, Canada</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Unutmaz</surname><given-names>Derya</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">New York University School of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>bnelson@bccancer.bc.ca</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: KM BN. Performed the experiments: KM. Analyzed the data: KM MK SEK DG CBG. Contributed reagents/materials/analysis tools: SEK RB. Wrote the paper: KM BN. Performed histological scoring: MK DG CBG. Contributed suggestions/revisions to paper: MK SEK RB CBG PHW. Ethics acquisition: RB.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2009</year></pub-date><volume>4</volume><issue>7</issue><elocation-id>e6412</elocation-id><history><date date-type="received"><day>19</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>26</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Milne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Tumor-infiltrating T cells are associated with survival in epithelial ovarian cancer (EOC), but their functional status is poorly understood, especially relative to the different risk categories and histological subtypes of EOC.</p></sec><sec><title>Methodology/Principal Findings</title><p>Tissue microarrays containing high-grade serous, endometrioid, mucinous and clear cell tumors were analyzed immunohistochemically for the presence of lymphocytes, dendritic cells, neutrophils, macrophages, MHC class I and II, and various markers of activation and inflammation. In high-grade serous tumors from optimally debulked patients, positive associations were seen between intraepithelial cells expressing CD3, CD4, CD8, CD45RO, CD25, TIA-1, Granzyme B, FoxP3, CD20, and CD68, as well as expression of MHC class I and II by tumor cells. Disease-specific survival was positively associated with the markers CD8, CD3, FoxP3, TIA-1, CD20, MHC class I and class II. In other histological subtypes, immune infiltrates were less prevalent, and the only markers associated with survival were MHC class II (positive association in endometrioid cases) and myeloperoxidase (negative association in clear cell cases).</p></sec><sec><title>Conclusions/Significance</title><p>Host immune responses to EOC vary widely according to histological subtype and the extent of residual disease. TIA-1, FoxP3 and CD20 emerge as new positive prognostic factors in high-grade serous EOC from optimally debulked patients.</p></sec></abstract><counts><page-count count="14"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Ovarian cancer is the most deadly gynecologic cancer, affecting more than 190,000 women worldwide each year (International Agency for Research on Cancer). Delayed diagnosis and the presence of widely disseminated disease account for the high mortality associated with the disease. Additionally, while a large percentage of patients initially respond well to cytoreductive surgery and standard chemotherapy, the disease usually recurs within 2-5 years as residual tumor cells develop resistance to chemotherapy <xref ref-type="bibr" rid="pone.0006412-Ozols1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-duBois1">&#x0005b;2&#x0005d;</xref>. Although prognosis is often poor, numerous favorable prognostic indicators have been described, including early stage, low grade and optimal surgical debulking <xref ref-type="bibr" rid="pone.0006412-Holschneider1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Ozols2">&#x0005b;4&#x0005d;</xref>.</p><p>Several recent studies have analyzed the influence of host immunity on disease prognosis. Tumor-infiltrating CD3&#x0002b; T cells are strongly associated with favorable prognosis, specifically when CD3&#x0002b; cells are localized within tumor epithelium <xref ref-type="bibr" rid="pone.0006412-Zhang1">&#x0005b;5&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Gimotty1">&#x0005b;9&#x0005d;</xref>. These findings have been extended to the CD8&#x0002b; T cell subset in particular <xref ref-type="bibr" rid="pone.0006412-Sato1">&#x0005b;10&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Han1">&#x0005b;17&#x0005d;</xref>, suggesting that cytotoxic T lymphocytes (CTLs) play an important role in the antitumor immune response. Accordingly, other factors associated with CTL responses are also positively associated with survival, including interferon-&#x003b3; (IFN- &#x003b3;) <xref ref-type="bibr" rid="pone.0006412-Marth1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Kusuda1">&#x0005b;19&#x0005d;</xref>, the IFN- &#x003b3; receptor <xref ref-type="bibr" rid="pone.0006412-Duncan1">&#x0005b;20&#x0005d;</xref>, interferon regulatory factor (IRF)-1 <xref ref-type="bibr" rid="pone.0006412-Zeimet1">&#x0005b;21&#x0005d;</xref>, IL-18 <xref ref-type="bibr" rid="pone.0006412-Akahiro1">&#x0005b;22&#x0005d;</xref>, TNF-&#x003b1; <xref ref-type="bibr" rid="pone.0006412-Bamias1">&#x0005b;23&#x0005d;</xref>, MHC class I <xref ref-type="bibr" rid="pone.0006412-Rolland1">&#x0005b;24&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Leffers2">&#x0005b;26&#x0005d;</xref>, and MHC class I antigen processing machinery <xref ref-type="bibr" rid="pone.0006412-Han1">&#x0005b;17&#x0005d;</xref>.</p><p>In contrast to CD8&#x0002b; T cells, several studies have indicated that tumor-infiltrating CD25&#x0002b;FoxP3&#x0002b; T cells (referred to as regulatory T cells or Tregs) are associated with decreased survival <xref ref-type="bibr" rid="pone.0006412-Sato1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Wolf1">&#x0005b;27&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Woo1">&#x0005b;29&#x0005d;</xref>. Tregs have the ability to suppress proliferation, cytokine production, and cytolytic activity of CD4&#x0002b; and CD8&#x0002b; T cells by mechanisms involving cell-to-cell contact and the release of cytokines such as TGF-&#x003b2; <xref ref-type="bibr" rid="pone.0006412-Miyara1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Piccirillo1">&#x0005b;31&#x0005d;</xref>. Tregs can also induce an immunosuppressive phenotype in other cell types such as macrophages <xref ref-type="bibr" rid="pone.0006412-Kryczek1">&#x0005b;32&#x0005d;</xref>. Although Tregs have been associated with poor prognosis in many cancers, several exceptions have recently been reported. Leffers et. al. found that FoxP3&#x0002b; infiltrates in advanced stage EOC were associated with increased survival <xref ref-type="bibr" rid="pone.0006412-Leffers1">&#x0005b;14&#x0005d;</xref>. Similar findings have been reported in colorectal cancer <xref ref-type="bibr" rid="pone.0006412-Salama1">&#x0005b;33&#x0005d;</xref> and lymphoma <xref ref-type="bibr" rid="pone.0006412-deJong1">&#x0005b;34&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Carreras1">&#x0005b;36&#x0005d;</xref>. Furthermore, in murine models, FoxP3&#x0002b; cells can play a positive role in anti-tumor and anti-viral immunity <xref ref-type="bibr" rid="pone.0006412-Erdman1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Lund1">&#x0005b;38&#x0005d;</xref>. The precise role of regulatory T cells in cancer outcomes warrants further consideration given that several groups are attempting to enhance tumor immunity by depleting FoxP3&#x0002b; Tregs from cancer patients <xref ref-type="bibr" rid="pone.0006412-Mahnke1">&#x0005b;39&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Rasku1">&#x0005b;44&#x0005d;</xref>, including EOC patients <xref ref-type="bibr" rid="pone.0006412-Barnett1">&#x0005b;45&#x0005d;</xref>.</p><p>In addition to Tregs, other cell types reportedly play an immunosuppressive role in EOC. For example, plasmacytoid dendritic cells contribute to immunosuppression by promoting the development or recruitment of interleukin-10-producing CD4&#x0002b; and CD8&#x0002b; regulatory T cells <xref ref-type="bibr" rid="pone.0006412-Wei1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Zou1">&#x0005b;47&#x0005d;</xref>. Myeloid dendritic cells (MDCs) impair T cell immunity by expressing B7-H1, a ligand for the inhibitory receptor PD-1 found on T cells <xref ref-type="bibr" rid="pone.0006412-Curiel2">&#x0005b;48&#x0005d;</xref>. Monocytes and macrophages in the EOC microenvironment can be polarized toward a so-called M2 phenotype, which is typified by the expression of IL-10, TGF-b and scavenger receptors and is thought to promote tumor progression <xref ref-type="bibr" rid="pone.0006412-Duluc1">&#x0005b;49&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Hagemann1">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Loercher1">&#x0005b;51&#x0005d;</xref>. Under the influence of IL-6 and IL-10, macrophages in EOC can also express B7-H4, which inhibits T cell proliferation <xref ref-type="bibr" rid="pone.0006412-Kryczek2">&#x0005b;52&#x0005d;</xref>. Macrophages also produce CCL22, which promotes Treg recruitment to the tumor environment <xref ref-type="bibr" rid="pone.0006412-Kryczek1">&#x0005b;32&#x0005d;</xref>. Finally, expression of the inflammatory mediator COX-2 in tumor epithelium has been associated with reduced lymphocyte infiltration and poor prognosis in EOC <xref ref-type="bibr" rid="pone.0006412-Liu1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Denkert1">&#x0005b;53&#x0005d;</xref>.</p><p>With the advent of tumor tissue microarray (TMA) technology, a large number of retrospective studies have investigated the relationship between tumor-infiltrating immune cells and prognosis in EOC and other cancers. However, most studies focus on one or a few markers, such that associations between different immunological factors may be missed. Additionally most studies fail to address the different histological subtypes of EOC, which are now recognized to behave as distinct diseases <xref ref-type="bibr" rid="pone.0006412-Kobel1">&#x0005b;54&#x0005d;</xref>. As a result, there are inconsistencies and unresolved issues in the literature concerning the prognostic significance of different immune cell infiltrates. To address this, we analyzed several large series of EOC tumors, including high-grade serous, endometrioid, clear cell and mucinous subtypes, for the presence of various immune cell infiltrates and inflammatory markers. Our results reveal that high-grade serous tumors have a distinct immunological profile that is strongly associated with patient survival.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Intraepithelial T cells and associated functional markers in high-grade serous EOC</title><p>We initially investigated the relationship between immune infiltrates and survival in a cohort of 199 high-grade serous EOC patients. We chose to first focus on high-grade serous cases, as the other histological subtypes exhibit distinct biological and clinical properties that are potentially confounding <xref ref-type="bibr" rid="pone.0006412-Kobel1">&#x0005b;54&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Gilks1">&#x0005b;55&#x0005d;</xref>. This initial cohort was restricted to patients who had undergone optimal cytoreduction (i.e., without evidence of macroscopic residual disease). Patient characteristics are shown in <xref ref-type="table" rid="pone-0006412-t001">Table 1</xref>.</p><table-wrap id="pone-0006412-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006412.t001</object-id><label>Table 1</label><caption><title>Clinical characteristics of the optimally debulked high-grade serous EOC patient cohort.</title></caption><alternatives><graphic id="pone-0006412-t001-1" xlink:href="pone.0006412.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">Age at surgery (years)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">61.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Std dev</td><td align="left" rowspan="1" colspan="1">11.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">37.59-85.96</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">60.08</td></tr><tr><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref> Overall Survival (years)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">5.59</td></tr><tr><td align="left" rowspan="1" colspan="1">Std dev</td><td align="left" rowspan="1" colspan="1">3.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">0.4-17.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">4.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Silverberg Grade</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">56</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">143</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">49</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">85</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="left" rowspan="1" colspan="1">65</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of evaluable patients</td><td align="left" rowspan="1" colspan="1">199</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>There were no deaths due to causes other than ovarian cancer, therefore disease-specific and overall survival were equivalent.</p></fn></table-wrap-foot></table-wrap><p>The tumors in this initial cohort had been previously assessed by immunohistochemistry (IHC) for a variety of lymphocyte markers, including CD3, CD4, CD8, CD20 and Granzyme B <xref ref-type="bibr" rid="pone.0006412-Clarke1">&#x0005b;12&#x0005d;</xref>. Intraepithelial lymphocytes (i.e., lymphocytes within the epithelial component of the tumor) were scored as either present (i.e. one or more intraepithelial lymphocytes present in at least one of two 0.6 mm cores) or absent. We re-analyzed this data focusing exclusively on high-grade serous cases. We found that 83.2&#x00025; (163/196) of evaluable high-grade serous tumors were positive for intraepithelial CD3&#x0002b; T cells, whereas CD4&#x0002b; and CD8&#x0002b; intraepithelial cells were found in 53.4&#x00025; (103/193) and 84.0&#x00025; (163/194) of evaluable tumors, respectively (<xref ref-type="fig" rid="pone-0006412-g001">Fig. 1A&#x00026;B</xref> and data not shown). CD4&#x0002b; and CD8&#x0002b; cellular infiltrates showed a strong positive association (p&#x0003c;0.0001). <xref ref-type="table" rid="pone-0006412-t002">Table 2</xref> shows statistical associations for these and all other markers studied in this initial cohort.</p><fig id="pone-0006412-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006412.g001</object-id><label>Figure 1</label><caption><title>Immunohistochemical analysis of high-grade serous EOC tumors showing infiltrates expressing markers of T cell differentiation and activation.</title><p>(A) CD4, (B) CD8, (C) CD45RO, (D) OX40, (E) CD25, (F) TIA-1, (G) Granzyme B, and (H) FoxP3. 40X objective.</p></caption><graphic xlink:href="pone.0006412.g001"/></fig><table-wrap id="pone-0006412-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006412.t002</object-id><label>Table 2</label><caption><title><italic>p</italic>-values for Chi-square tests of associations between immunohistochemical markers in the optimally debulked high-grade serous EOC cohort.</title></caption><alternatives><graphic id="pone-0006412-t002-2" xlink:href="pone.0006412.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CD3</td><td align="left" rowspan="1" colspan="1">CD8</td><td align="left" rowspan="1" colspan="1">CD4</td><td align="left" rowspan="1" colspan="1">CD45R0</td><td align="left" rowspan="1" colspan="1">CD25</td><td align="left" rowspan="1" colspan="1">OX40</td><td align="left" rowspan="1" colspan="1">TIA-1</td><td align="left" rowspan="1" colspan="1">GrB<xref ref-type="table-fn" rid="nt102">1</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>CD3</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD8</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD4</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.0021</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.049</td><td align="left" rowspan="1" colspan="1">0.0013</td><td align="left" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD45RO</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0021</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD25</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.0040</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>OX40</bold></td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">0.049</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.0040</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TIA-1</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0013</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GrB</bold><xref ref-type="table-fn" rid="nt102">1</xref></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.044</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FoxP3</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MHC I</bold><xref ref-type="table-fn" rid="nt103">2</xref></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MHC II</bold><xref ref-type="table-fn" rid="nt104">3</xref></td><td align="left" rowspan="1" colspan="1">0.0078</td><td align="left" rowspan="1" colspan="1">0.0009</td><td align="left" rowspan="1" colspan="1">0.013</td><td align="left" rowspan="1" colspan="1">0.0004</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.38</td><td align="left" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD20</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">0.0036</td><td align="left" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD1a</bold></td><td align="left" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">0.096</td><td align="left" rowspan="1" colspan="1">0.046</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD68</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.0028</td><td align="left" rowspan="1" colspan="1">0.0019</td><td align="left" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">0.0005</td><td align="left" rowspan="1" colspan="1">0.0007</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MPO</bold><xref ref-type="table-fn" rid="nt105">4</xref></td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="left" rowspan="1" colspan="1">0.78</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>COX-2</bold><xref ref-type="table-fn" rid="nt106">5</xref></td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">0.55</td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>FoxP3</bold></td><td align="left" rowspan="1" colspan="1"><bold>MHC I</bold><xref ref-type="table-fn" rid="nt103">2</xref></td><td align="left" rowspan="1" colspan="1"><bold>MHC II</bold><xref ref-type="table-fn" rid="nt104">3</xref></td><td align="left" rowspan="1" colspan="1"><bold>CD20</bold></td><td align="left" rowspan="1" colspan="1"><bold>CD1a</bold></td><td align="left" rowspan="1" colspan="1"><bold>CD68</bold></td><td align="left" rowspan="1" colspan="1"><bold>MPO</bold><xref ref-type="table-fn" rid="nt105">4</xref></td><td align="left" rowspan="1" colspan="1"><bold>COX2</bold><xref ref-type="table-fn" rid="nt106">5</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD3</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0078</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD8</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0009</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.096</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD4</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.013</td><td align="left" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">0.046</td><td align="left" rowspan="1" colspan="1">0.0028</td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD45RO</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0004</td><td align="left" rowspan="1" colspan="1">0.0036</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">0.0019</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD25</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">0.78</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>OX40</bold></td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.38</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TIA-1</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">0.0005</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GrB</bold><xref ref-type="table-fn" rid="nt102">1</xref></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.016</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.48</td><td align="left" rowspan="1" colspan="1">0.0007</td><td align="left" rowspan="1" colspan="1">0.49</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FoxP3</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0009</td><td align="left" rowspan="1" colspan="1">0.35</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MHC I</bold><xref ref-type="table-fn" rid="nt103">2</xref></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">0.0015</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.035</td><td align="left" rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MHC II</bold><xref ref-type="table-fn" rid="nt104">3</xref></td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.023</td><td align="left" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD20</bold></td><td align="left" rowspan="1" colspan="1">0.0009</td><td align="left" rowspan="1" colspan="1">0.0015</td><td align="left" rowspan="1" colspan="1">0.023</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD1a</bold></td><td align="left" rowspan="1" colspan="1">0.35</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">0.046</td><td align="left" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD68</bold></td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.035</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MPO</bold><xref ref-type="table-fn" rid="nt105">4</xref></td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">0.046</td><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>COX-2</bold><xref ref-type="table-fn" rid="nt106">5</xref></td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">0.17</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.84</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="left" rowspan="1" colspan="1">0.51</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label>1</label><p>GrB &#x0200a;&#x0003d;&#x0200a; Granzyme B.</p></fn><fn id="nt103"><label>2</label><p>MHC I &#x0200a;&#x0003d;&#x0200a; MHC class I.</p></fn><fn id="nt104"><label>3</label><p>MHC II &#x0200a;&#x0003d;&#x0200a; MHC class II.</p></fn><fn id="nt105"><label>4</label><p>MPO &#x0200a;&#x0003d;&#x0200a; myeloperoxidase.</p></fn><fn id="nt106"><label>5</label><p>COX-2 &#x0200a;&#x0003d;&#x0200a; Cyclooxygenase-2.</p></fn></table-wrap-foot></table-wrap><p>While the above markers indicate which lymphocyte subsets are present in tumors, they do not reveal their activation state. To address this issue, we analyzed tumors for expression of CD45RO, OX40 and CD25, which are expressed by activated T cells <xref ref-type="bibr" rid="pone.0006412-Brenchley1">&#x0005b;56&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Weinberg1">&#x0005b;57&#x0005d;</xref>. Using the same scoring criteria as above, 70.6&#x00025; (132/187) of tumors were positive for intraepithelial CD45RO&#x0002b; cells, and 49.7&#x00025; (96/193) were positive for intraepithelial CD25&#x0002b; cells (<xref ref-type="fig" rid="pone-0006412-g001">Fig. 1C&#x00026;E</xref>). By contrast, only 7.0&#x00025; (11/158) of tumors were positive for intraepithelial OX40&#x0002b; cells (<xref ref-type="fig" rid="pone-0006412-g001">Fig. 1D</xref>). In pair-wise comparisons, CD45RO, CD25 and OX40 were all positively associated (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>). Moreover, CD45RO and CD25 were both associated with the presence of CD3&#x0002b;, CD4&#x0002b; and CD8&#x0002b; cells. OX40 showed a similar trend, but this did not reach statistical significance, likely due to the low number of positive cases.</p><p>To investigate the differentiation state of tumor-infiltrating T cells, tissues were analyzed for intraepithelial cells expressing TIA-1 and Granzyme B, which are markers of CD8&#x0002b; cytotoxic T cells and NK cells <xref ref-type="bibr" rid="pone.0006412-Pipkin1">&#x0005b;58&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Kanavaros1">&#x0005b;60&#x0005d;</xref>. A majority of tumors (66.5&#x00025;, 127/191) were positive for intraepithelial TIA-1&#x0002b; cells (<xref ref-type="fig" rid="pone-0006412-g001">Fig. 1F</xref>), and about half of tumors (45.6&#x00025;, 88/193) were positive for intraepithelial Granzyme B&#x0002b; cells (<xref ref-type="fig" rid="pone-0006412-g001">Fig. 1G</xref>). There was a highly significant association between TIA-1&#x0002b; and Granzyme B&#x0002b; cells (p&#x0003c;0.0001). Moreover, in pair-wise comparisons, TIA-1&#x0002b; and Granzyme B&#x0002b; cells were each associated with the activation markers CD45RO, CD25 and OX40. Finally, TIA-1&#x0002b; and Granzyme B&#x0002b; cells were each associated with the presence of CD3&#x0002b;, CD4&#x0002b; and CD8&#x0002b; cells (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>). To examine whether TIA-1 and Granzyme B expression could be due to the presence of NK or NKT cells, we examined tumors for the NK cell markers CD56 and CD57. For both markers, there were either few or no infiltrates at all within the tumor epithelium (data not shown), indicating that the TIA-1&#x0002b; and Granzyme B&#x0002b; infiltrates were most likely T cells.</p><p>Finally, tumors were analyzed for the presence of intraepithelial cells expressing FoxP3, which in humans is a marker of regulatory T cells and activated T cells <xref ref-type="bibr" rid="pone.0006412-Ziegler1">&#x0005b;61&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Zou2">&#x0005b;62&#x0005d;</xref>. About half of tumors (52.9&#x00025;, 100/189) were positive for intraepithelial FoxP3&#x0002b; cells (<xref ref-type="fig" rid="pone-0006412-g001">Fig. 1H</xref>). There was a strong association between FoxP3&#x0002b; and CD25&#x0002b; cells (p&#x0003c;0.0001), and FoxP3&#x0002b; and CD25&#x0002b; cells were each strongly associated with CD4&#x0002b; cells (p&#x0003c;0.0001 for both markers). Thus, consistent with previous reports <xref ref-type="bibr" rid="pone.0006412-Sato1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Leffers1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Wolf1">&#x0005b;27&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Curiel1">&#x0005b;28&#x0005d;</xref>, a significant proportion of tumors contained intraepithelial infiltrates with markers characteristic of Tregs (CD4&#x0002b;,CD25&#x0002b;, and FoxP3&#x0002b;).</p></sec><sec id="s2b"><title>MHC class I and II in high-grade serous EOC</title><p>We analyzed tumor cells for expression of MHC class I and II using a four-point scale (negative, focal &#x0005b;&#x0003c;10&#x00025;&#x0005d;, patchy &#x0005b;10-50&#x00025;&#x0005d; or diffuse &#x0005b;&#x0003e;50&#x00025;&#x0005d;). All evaluable tumors (185/185) expressed MHC class I to some degree (i.e., focal, patchy or diffuse), indicating they could theoretically present antigen to CD8&#x0002b; T cells. For statistical analyses, only the highest category (diffuse, &#x0003e;50&#x00025;) was considered positive (<xref ref-type="fig" rid="pone-0006412-g002">Fig. 2A&#x00026;B</xref>). Using this threshold, 85.4&#x00025; (158/185) of tumors were positive for MHC class I. MHC class I was positively associated with all three T cell subsets (CD3, CD4, and CD8), the activation markers CD45RO and CD25, and the differentiation markers TIA-1, Granzyme B and FoxP3 (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>).</p><fig id="pone-0006412-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006412.g002</object-id><label>Figure 2</label><caption><title>Immunohistochemical analysis of high-grade serous EOC tumors showing (A,B) high and low expression of MHC class I, (C,D) high and low expression of MHC class II, and (E,F) high and low expression of COX-2.</title><p>40X objective.</p></caption><graphic xlink:href="pone.0006412.g002"/></fig><p>A large majority of tumors (86.5&#x00025;, 166/192) expressed MHC class II to some degree (i.e., focal, patchy or diffuse), indicating they could theoretically present antigen to CD4&#x0002b; T cells. As with MHC class I, only the highest category (diffuse, &#x0003e;50&#x00025;) was considered positive for statistical analyses (<xref ref-type="fig" rid="pone-0006412-g002">Fig. 2 C&#x00026;D</xref>). Using this threshold, 41.1&#x00025; (79/192) of tumors were positive for MHC class II. MHC class II was strongly associated with MHC class I (p&#x0003c;0.0001). Accordingly, MHC class II was positively associated with all three T cell subsets (CD3, CD4, and CD8), the activation markers CD45RO and CD25, and the differentiation markers TIA-1, Granzyme B and FoxP3 (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>). Similar to the results for MHC class I, the expression of MHC class II in tumor epithelium was positively associated with various T cell markers, including CD3, CD4, CD8, CD45RO, TIA-1, Granzyme B, CD25 and FoxP3 (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>).</p></sec><sec id="s2c"><title>Intraepithelial B cells in high-grade serous EOC</title><p>Tissues were stained with an antibody to CD20, which is expressed by B cells from the na&#x000ef;ve to memory stages of differentiation <xref ref-type="bibr" rid="pone.0006412-Edwards1">&#x0005b;63&#x0005d;</xref>. Intraepithelial CD20&#x0002b; cells were found in 41.9&#x00025; (83/198) of evaluable tumors (<xref ref-type="fig" rid="pone-0006412-g003">Fig. 3A</xref>). CD20&#x0002b; infiltrates were strongly associated with all three T cell subsets (CD3, CD4, and CD8); the activation markers CD45RO and CD25; the differentiation markers TIA-1, Granzyme B and FoxP3; and both MHC class I and II (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>).</p><fig id="pone-0006412-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006412.g003</object-id><label>Figure 3</label><caption><title>Immunohistochemical analysis of high-grade serous EOC tumors showing infiltrates expressing (A) CD20 (B cells), (B) CD1a (immature DCs), (C) Myeloperoxidase (granulocytes), and (D) CD68 (macrophages).</title><p>40X objective.</p></caption><graphic xlink:href="pone.0006412.g003"/></fig></sec><sec id="s2d"><title>Intraepithelial dendritic cells, granulocytes and macrophages in high-grade serous EOC</title><p>Tumors were analyzed for the presence of immature and mature dendritic cells by staining for CD1a and CD208, respectively. A minority of tumors (13.4&#x00025;, 23/172) contained intraepithelial CD1a&#x0002b; cells (<xref ref-type="fig" rid="pone-0006412-g003">Fig. 3B</xref>). No significant association with any of the intraepithelial lymphocyte markers (CD3, CD8 or CD20), activation markers (CD45RO or CD25), differentiation markers (TIA-1, Granzyme B or FoxP3) or MHC class I or II (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>) was seen, potentially due to the low number of CD1a&#x0002b; cells. In contrast to CD1a, none of the tumors scored positive for intraepithelial CD208&#x0002b; cells. Parallel analysis of tonsil tissue revealed the presence of many CD208&#x0002b; cells, thereby validating the IHC procedure.</p><p>About half of tumors (54.7&#x00025;, 87/159) contained intraepithelial cells expressing the macrophage marker CD68 (<xref ref-type="fig" rid="pone-0006412-g003">Fig. 3D</xref>). CD68 was positively associated with several lymphocyte markers (CD3, CD8 and CD20), activation markers (CD45RO and CD25), differentiation markers (TIA-1, Granzyme B and FoxP3) and MHC class I (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>). To assess the presence of granulocytes, the TMA was stained for myeloperoxidase. Twenty four percent (37/154) of tumors contained myeloperoxidase-expressing cells (<xref ref-type="fig" rid="pone-0006412-g003">Fig. 3C</xref>), however these showed no significant associations with other markers, with the exception of CD4 (p&#x0200a;&#x0003d;&#x0200a;0.034).</p><p>The COX-2 enzyme has been associated with inferior survival in EOC when expressed in the epithelial component of the tumor <xref ref-type="bibr" rid="pone.0006412-Denkert1">&#x0005b;53&#x0005d;</xref>. Therefore, tumors were scored for expression of COX-2 in the epithelial component using a four-point scale (negative, equivocal &#x0005b;0-1&#x00025;&#x0005d;, patchy &#x0005b;1-50&#x00025;&#x0005d; or diffuse &#x0005b;&#x0003e;50&#x00025;&#x0005d;) (<xref ref-type="fig" rid="pone-0006412-g002">Fig. 2E&#x00026;F</xref>). Two-thirds of tumors (66.5&#x00025;, 111/167) were positive for COX-2 (i.e., patchy or diffuse staining). In contrast to reports in ovarian, cervical, and other cancers, <xref ref-type="bibr" rid="pone.0006412-Liu1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Ahmadi1">&#x0005b;64&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Lang1">&#x0005b;65&#x0005d;</xref>, the expression of COX-2 was not significantly associated with any of the immune infiltrates studied (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>).</p></sec><sec id="s2e"><title>Associations between immune infiltrates and patient survival in high-grade serous EOC</title><p>Kaplan-Meier analysis was performed to assess the association between various immune infiltrates and disease-specific survival (DSS). Consistent with prior reports <xref ref-type="bibr" rid="pone.0006412-Zhang1">&#x0005b;5&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Tomsova1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Sato1">&#x0005b;10&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Han1">&#x0005b;17&#x0005d;</xref>, intraepithelial CD3&#x0002b; and CD8&#x0002b; cells were associated with increased DSS (p&#x0200a;&#x0003d;&#x0200a;0.0009 and 0.0008 respectively) (<xref ref-type="fig" rid="pone-0006412-g004">Fig. 4A&#x00026;B</xref>). Intraepithelial CD4&#x0002b; cells showed a trend towards increased DSS, but this was not statistically significant (<xref ref-type="fig" rid="pone-0006412-g004">Fig. 4C</xref>). The NK cell markers CD56 and CD57 showed no association with DSS (data not shown).</p><fig id="pone-0006412-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006412.g004</object-id><label>Figure 4</label><caption><title>Immune infiltrates and survival in ovarian cancer.</title><p>Kaplan-Meier curves showing disease-specific survival for patients scored as positive or negative for (A) CD3, (B) CD8, (C) CD4, (D) FoxP3, (E) CD20, (F) CD68, (G) TIA-1, (H) Granzyme B, (I) MHC Class I and (J) MHC Class II. Data were derived from optimally debulked patients with high-grade serous EOC.</p></caption><graphic xlink:href="pone.0006412.g004"/></fig><p>Intriguingly, intraepithelial CD20&#x0002b; cells were associated with increased DSS (p&#x0200a;&#x0003d;&#x0200a;0.0033) (<xref ref-type="fig" rid="pone-0006412-g004">Fig. 4E</xref>). Furthermore, the combination of CD8&#x0002b; and CD20&#x0002b; infiltrates was associated with significantly increased DSS over tumors that contained CD8&#x0002b; infiltrates but not CD20&#x0002b; infiltrates (median 4432 days vs. 2279 days, p&#x0200a;&#x0003d;&#x0200a;0.0115) (data not shown).</p><p>In contrast to lymphocyte markers, the dendritic cell marker CD1a showed no association with DSS, possibly due to the low number of tumors containing CD1a&#x0002b; cells. Likewise, the markers CD68, COX-2 and myeloperoxidase showed no association with DSS (<xref ref-type="fig" rid="pone-0006412-g004">Fig. 4F</xref> and data not shown).</p><p>Given the association between CD8&#x0002b; T cells and DSS, we evaluated other canonical features of active CTL responses. DSS was positively associated with intraepithelial TIA-1&#x0002b; cells (p&#x0200a;&#x0003d;&#x0200a;0.0003), as well as expression of MHC class I and II by tumor cells (p&#x0200a;&#x0003d;&#x0200a;0.0014 and 0.0026 respectively) (<xref ref-type="fig" rid="pone-0006412-g004">Fig. 4G,I,&#x00026;J</xref>). Tumors that contained both CD8&#x0002b; and TIA-1&#x0002b; infiltrates were associated with increased DSS compared to CD8&#x0002b; TIA-1-negative tumors (p&#x0200a;&#x0003d;&#x0200a;0.0025). Several other T cell markers, including Granzyme B, CD45RO and CD25, showed trends toward increased DSS but did not reach statistical significance (<xref ref-type="fig" rid="pone-0006412-g004">Fig. 4H</xref> and data not shown). OX-40 showed no apparent trend or association with DSS, possibly due to low numbers of positive cases (data not shown).</p><p>In apparent contrast to reports that regulatory T cells are associated with poor prognosis, the presence of intraepithelial FoxP3&#x0002b; cells was associated with increased DSS (p&#x0200a;&#x0003d;&#x0200a;0.010) (<xref ref-type="fig" rid="pone-0006412-g004">Fig. 4D</xref>). Moreover, tumors that were triply positive for intraepithelial CD4&#x0002b;, FoxP3&#x0002b; and CD25&#x0002b; cells showed a trend towards increased survival, although this fell short of statistical significance (p&#x0200a;&#x0003d;&#x0200a;0.059). Likewise, tumors positive for both intraepithelial CD8&#x0002b; and FoxP3&#x0002b; cells showed a trend toward increased DSS compared to tumors that were positive for CD8&#x0002b; cells but negative for FoxP3&#x0002b; cells; however, this trend did not reach statistical significance (p&#x0200a;&#x0003d;&#x0200a;0.052). Thus, by multiple analyses, tumor-infiltrating FoxP3&#x0002b; cells showed a trend or statistically significant association with increased DSS.</p></sec><sec id="s2f"><title>The association between immune infiltrates and survival is dependent on the extent of residual disease</title><p>T cell infiltrates are reportedly more prevalent in patients with optimal versus suboptimal cytoreduction <xref ref-type="bibr" rid="pone.0006412-Zhang1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Shah1">&#x0005b;66&#x0005d;</xref>. To investigate whether this was true for other lymphocyte markers, we analyzed an additional cohort of 220 high-grade serous cases from patients known to have macroscopic residual disease following primary cytoreductive surgery. We focused on CD8&#x0002b; infiltrates, as well as the three novel prognostic markers from the preceding analysis (i.e., FoxP3, TIA-1 and CD20). Compared to the optimally debulked patient cohort, patients with macroscopic residual disease had a significantly lower prevalence of CD8&#x0002b; (58.5&#x00025;), FoxP3&#x0002b; (20.2&#x00025;), TIA-1&#x0002b; (39.5&#x00025;) and CD20&#x0002b; (16.3&#x00025;) infiltrates (p&#x0003c;0.0001 for all markers). In Kaplan-Meier analysis of these four markers, only CD8&#x0002b; infiltrates had a significant association with survival (p&#x0200a;&#x0003d;&#x0200a;0.0044) in patients with macroscopic residual disease (data not shown).</p></sec><sec id="s2g"><title>The association between immune infiltrates and survival is dependent on histological subtype</title><p>The preceding results were based exclusively on high-grade serous EOC cases. To assess the association between immune infiltrates and DSS in other histological subtypes of EOC, we performed the same analyses using an additional 288 EOC tumors of the following histological subtypes: mucinous (n&#x0200a;&#x0003d;&#x0200a;31), endometrioid (n&#x0200a;&#x0003d;&#x0200a;125) and clear cell (n&#x0200a;&#x0003d;&#x0200a;132). These additional tumor specimens were from a previously described cohort of optimally debulked patients <xref ref-type="bibr" rid="pone.0006412-Clarke1">&#x0005b;12&#x0005d;</xref>.</p><p>In general, immune infiltrates were less prevalent in the other histological subtypes compared to the high-grade serous cases discussed previously. This was true for all lymphocyte markers studied (i.e., CD3, CD8, CD4, CD45RO, CD25, FoxP3, TIA-1, Granzyme B, and CD20) (<xref ref-type="fig" rid="pone-0006412-g005">Fig. 5</xref>). The difference was most striking for the markers FoxP3, CD25 and CD20. After the high-grade serous cases, the next highest frequency of immune infiltrates was seen in the endometrioid subtype (<xref ref-type="fig" rid="pone-0006412-g005">Fig. 5</xref>).</p><fig id="pone-0006412-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006412.g005</object-id><label>Figure 5</label><caption><title>Prevalence of immune infiltrates and other markers across different histologic subtypes of EOC.</title><p>Bars indicate the percentage of tumors scoring positive for intrapithelial cells expressing CD3, CD8, CD4, CD45RO, CD25, FoxP3, TIA-1, Granzyme B, CD20 and CD68. Expression of MHC class I and II by tumor epithelium is also shown. Data were derived from optimally debulked patients.</p></caption><graphic xlink:href="pone.0006412.g005"/></fig><p>We examined the association between immune infiltrates and DSS in the endometrioid and clear cell subtypes; the number of mucinous cases was too small to perform robust statistical analysis. For endometrioid cases, the only significant association found was between MHC class II expression and increased DSS (p&#x0200a;&#x0003d;&#x0200a;0.039) (data not shown). For clear cell cases, the only significant association found was between the presence of myeloperoxidase-positive infiltrates and decreased DSS (p&#x0200a;&#x0003d;&#x0200a;0.040, data not shown). Thus, the relationship between immune infiltrates and survival differs greatly between histological subtypes of EOC.</p></sec></sec><sec id="s3"><title>Discussion</title><p>We systematically examined the relationship between immune infiltrates and patient survival in three large EOC series. In accord with Clarke et al. <xref ref-type="bibr" rid="pone.0006412-Clarke1">&#x0005b;12&#x0005d;</xref>, we found that high-grade serous tumors have a distinct immunological profile compared to the endometrioid, clear cell and mucinous subtypes. Furthermore, we found that immune infiltrates were generally more prevalent in tumors from patients with optimal cytoreduction. FoxP3, TIA-1 and CD20 emerged as novel immunological markers associated with increased patient survival. Our results highlight the importance of histological subtype in the immunobiology of EOC, which may have important implications for the immunotherapy of this family of diseases.</p><p>Intraepithelial lymphocytes (i.e., cells expressing CD3, CD4, CD8, FoxP3 or CD20) were more prevalent in high-grade serous cases, followed by endometrioid cases. Moreover, intraepithelial lymphocytes were more prevalent in tumors from optimally debulked patients compared to patients with macroscopic residual disease. A number of biological features of tumors appear to influence the density of lymphocytic infiltrates. (a) T cell infiltrates are positively associated with expression of MHC class I and II by tumor cells (<xref ref-type="table" rid="pone-0006412-t002">Table 2</xref>), as well as MHC class I antigen processing machinery <xref ref-type="bibr" rid="pone.0006412-Callahan1">&#x0005b;15&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Han1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Kooi1">&#x0005b;67&#x0005d;</xref>, suggesting that antigen presentation may be an important determinant of T cell infiltration. (b) In accord with this notion, tumors with loss or mutation of the BRCA1 or p53 genes have an increased density of tumor-infiltrating T cells <xref ref-type="bibr" rid="pone.0006412-Clarke1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Shah1">&#x0005b;66&#x0005d;</xref>. This suggests that defective DNA repair and the ensuing genomic instability in tumors may lead to the generation of neo-antigens that trigger host T cell responses. (c) Signaling molecules also play a role, as the density of tumor-infiltrating T cells is negatively associated with expression of VEGF, B7-H1/PD-L1 and endothelin B receptor by tumors <xref ref-type="bibr" rid="pone.0006412-Zhang1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Hamanishi1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Buckanovich1">&#x0005b;68&#x0005d;</xref> and positively associated with expression of the chemokines CXCL9, CCL21, CCL22, CCL2 and CCL5 <xref ref-type="bibr" rid="pone.0006412-Zhang1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Curiel1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Negus1">&#x0005b;69&#x0005d;</xref>. (d) Finally, two groups have reported gene expression profiles that correlate with the presence of tumor-infiltrating T cells in EOC <xref ref-type="bibr" rid="pone.0006412-Clarke1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Tothill1">&#x0005b;70&#x0005d;</xref>. These latter studies confirm some of the above associations (e.g., MHC class I and II, beta 2 microglobulin, TAP1 and 2) and identify new factors associated with T cell infiltrates (e.g., IL-15, IL-32 and numerous interferon-induced genes). Presumably one or more of the above factors accounts for the observed enrichment of tumor-infiltrating lymphocytes in high-grade serous and optimally cytoreduced cases.</p><p>Although the association between intraepithelial CD8&#x0002b; T cells and increased survival in EOC is a highly reproducible finding <xref ref-type="bibr" rid="pone.0006412-Sato1">&#x0005b;10&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Han1">&#x0005b;17&#x0005d;</xref>, relatively little is known about the functional phenotype of these CD8&#x0002b; T cells. Several lines of evidence suggest a classic cytolytic response underlies favorable outcomes. For example, others have reported positive associations between survival and intratumoral expression of IFN- &#x003b3; <xref ref-type="bibr" rid="pone.0006412-Marth1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Kusuda1">&#x0005b;19&#x0005d;</xref>, the IFN- &#x003b3; receptor <xref ref-type="bibr" rid="pone.0006412-Duncan1">&#x0005b;20&#x0005d;</xref>, as well as numerous interferon-responsive genes such as MHC class I <xref ref-type="bibr" rid="pone.0006412-Rolland1">&#x0005b;24&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Leffers2">&#x0005b;26&#x0005d;</xref>, MHC class I antigen processing machinery <xref ref-type="bibr" rid="pone.0006412-Han1">&#x0005b;17&#x0005d;</xref>, MHC class II <xref ref-type="bibr" rid="pone.0006412-Callahan1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Matsushita1">&#x0005b;16&#x0005d;</xref>, and IRF-1 <xref ref-type="bibr" rid="pone.0006412-Zeimet1">&#x0005b;21&#x0005d;</xref>. IL-18 <xref ref-type="bibr" rid="pone.0006412-Akahiro1">&#x0005b;22&#x0005d;</xref> and TNF-&#x003b1; <xref ref-type="bibr" rid="pone.0006412-Bamias1">&#x0005b;23&#x0005d;</xref> also appear to be important components of the T cell response, as both cytokines are positively associated with survival. We examined two components of cytolytic granules, Granzyme B and TIA-1, both of which showed an association with CD8&#x0002b; T cell infiltrates. Of these two markers, only TIA-1 showed a statistically significant association with survival in high-grade serous cases (<xref ref-type="fig" rid="pone-0006412-g004">Fig. 4</xref>). TIA-1&#x0002b; cells have also been described in medullary breast cancer <xref ref-type="bibr" rid="pone.0006412-Kuroda1">&#x0005b;71&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Yakirevich1">&#x0005b;72&#x0005d;</xref> and melanoma <xref ref-type="bibr" rid="pone.0006412-Lyle1">&#x0005b;73&#x0005d;</xref>, where they are associated with favorable prognostic features. By contrast, tumor-infiltrating TIA-1&#x0002b; cells are associated with decreased survival in lymphoma <xref ref-type="bibr" rid="pone.0006412-Hasselblom1">&#x0005b;74&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Alvaro1">&#x0005b;78&#x0005d;</xref>. Interestingly, TIA-1 is not simply a marker of cytolytic granules; it is an RNA binding protein involved in post-transcriptional mRNA regulation <xref ref-type="bibr" rid="pone.0006412-Anderson1">&#x0005b;79&#x0005d;</xref>. It remains to be determined whether the association between intraepithelial TIA-1&#x0002b; cells and survival in EOC is due to the role of this protein in cytolytic granule function or mRNA regulation.</p><p>Treg infiltrates have previously been associated with decreased survival in ovarian EOC <xref ref-type="bibr" rid="pone.0006412-Sato1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Wolf1">&#x0005b;27&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Curiel1">&#x0005b;28&#x0005d;</xref>. However, in the present study and one other recent report <xref ref-type="bibr" rid="pone.0006412-Leffers1">&#x0005b;14&#x0005d;</xref>, FoxP3&#x0002b; infiltrates were associated with increased survival. These seemingly contradictory findings may be attributable to several factors. First, not all studies take into consideration the histological subtypes of EOC, or the extent of residual disease; in the present study, FoxP3&#x0002b; cells were only associated with survival in high-grade serous tumors from optimally debulked patients. Second, a variety of antibodies have been used to detect FoxP3, which can lead to discordant results <xref ref-type="bibr" rid="pone.0006412-Woo2">&#x0005b;80&#x0005d;</xref>. Third, different scoring criteria may be used. For example, the precise intratumoral location of Tregs is an important determinant of prognosis in gastric cancer <xref ref-type="bibr" rid="pone.0006412-Mizukami1">&#x0005b;81&#x0005d;</xref>. Fourth, the molecular markers used to define Tregs differ between studies. Although FoxP3 is still regarded as the most reliable marker of Tregs in human cancer <xref ref-type="bibr" rid="pone.0006412-Ahmadzadeh1">&#x0005b;82&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Kryczek3">&#x0005b;83&#x0005d;</xref>, it can also be expressed by epithelial tumor cells <xref ref-type="bibr" rid="pone.0006412-Karanikas1">&#x0005b;84&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Ebert1">&#x0005b;86&#x0005d;</xref> and <italic>in vitro</italic> activated CD4&#x0002b; and CD8&#x0002b; T cells <xref ref-type="bibr" rid="pone.0006412-Walker1">&#x0005b;87&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Imamichi1">&#x0005b;95&#x0005d;</xref>. For these reasons, some studies include CD25 as a second marker of Tregs <xref ref-type="bibr" rid="pone.0006412-Sato1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Curiel1">&#x0005b;28&#x0005d;</xref>. However, like FoxP3, CD25 is potentially expressed by effector T cells, so it is not clear that dual staining for FoxP3 and CD25 more accurately identifies Tregs <xref ref-type="bibr" rid="pone.0006412-Roncador1">&#x0005b;89&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Roncarolo1">&#x0005b;96&#x0005d;</xref>. Other characteristics of Tregs include high expression of GITR and CTLA-4 and low expression of CD127 and CD49d and <xref ref-type="bibr" rid="pone.0006412-Kleinewietfeld1">&#x0005b;97&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Banham1">&#x0005b;98&#x0005d;</xref>, however these markers are technically difficult to assess on paraffin-embedded TMAs.</p><p>These technical considerations notwithstanding, there is mounting evidence that tumor-infiltrating FoxP3&#x0002b; cells are associated with a favorable prognosis in EOC, colorectal cancer, head and neck cancer, and lymphoma &#x0005b;14,33,-36,99-102&#x0005d;. How might FoxP3&#x0002b; T cells promote favorable outcomes? In the present study, FoxP3&#x0002b; cells were strongly associated with other effector T cells, and similar results have been reported in melanoma <xref ref-type="bibr" rid="pone.0006412-Hillen1">&#x0005b;103&#x0005d;</xref>. Thus, FoxP3&#x0002b; cells may simply be an indicator of a strong CD8&#x0002b; T cell response, which might outweigh any immunosuppressive effects of FoxP3&#x0002b; cells. Alternatively, subsets of human FoxP3&#x0002b; T cells have recently been shown to have a pro-inflammatory, IL-17-producing phenotype <xref ref-type="bibr" rid="pone.0006412-Ayyoub1">&#x0005b;104&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Koenen1">&#x0005b;106&#x0005d;</xref>. Indeed, CD4&#x0002b; T cells can be skewed toward this so-called Th17 phenotype by exposure to TGF-&#x003b2; in combination with IL-6, IL-1 or IL-23 <xref ref-type="bibr" rid="pone.0006412-Bettelli1">&#x0005b;107&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Stockinger1">&#x0005b;109&#x0005d;</xref>. These factors are present in the EOC tumor environment <xref ref-type="bibr" rid="pone.0006412-Nelson1">&#x0005b;8&#x0005d;</xref>, and accordingly, Th17 cells have been reported in EOC <xref ref-type="bibr" rid="pone.0006412-Kato1">&#x0005b;110&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Leveque1">&#x0005b;112&#x0005d;</xref>. Thus, the association between FoxP3&#x0002b; cells and increased survival could potentially reflect an underlying Th17-like anti-tumor response. Clearly, more work is required to determine the extent to which FoxP3&#x0002b; T cells in EOC represent Tregs versus Th17 or other effector T cells.</p><p>The observation that intraepithelial CD20&#x0002b; infiltrates are associated with increased DSS is a novel finding in EOC. Dong et. al. reported that B cells in ascites were associated with shorter survival in EOC <xref ref-type="bibr" rid="pone.0006412-Dong1">&#x0005b;113&#x0005d;</xref>, however their study focused on B cells in peritoneal and pleural effusions collected after chemotherapy, which by definition constitutes a poor outcome cohort. Indeed, in the present study, intraepithelial CD20&#x0002b; B cells showed no association with survival in patients with high-risk, suboptimally debulked disease. Tumor-infiltrating CD20&#x0002b; B cells are a hallmark of medullary breast cancer and have been proposed to mediate a favorable prognosis <xref ref-type="bibr" rid="pone.0006412-Hansen1">&#x0005b;114&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Hansen2">&#x0005b;115&#x0005d;</xref>. Moreover, the presence of a B cell transcriptional signature in node-negative breast cancer is associated with increased survival <xref ref-type="bibr" rid="pone.0006412-Schmidt1">&#x0005b;116&#x0005d;</xref>. B cell infiltrates in breast cancer represent clonally expanded populations, express somatically hypermutated IgG molecules, and recognize target antigens such as ganglioside D3 and surface-translocated actin <xref ref-type="bibr" rid="pone.0006412-Hansen1">&#x0005b;114&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Hansen2">&#x0005b;115&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Wang2">&#x0005b;117&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Nzula1">&#x0005b;120&#x0005d;</xref>. It is unclear how tumor-infiltrating B cells promote favorable outcomes in cancer. In theory, their actions could be mediated by secreted antibodies, which can promote the opsonization of tumor antigens, complement-mediated destruction of tumor cells, or antibody-dependent cellular cytotoxicity. Apart from producing antibodies, B cells can also present antigen to both CD4&#x0002b; and CD8&#x0002b; T cells <xref ref-type="bibr" rid="pone.0006412-KurtJones1">&#x0005b;121&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Ronchese1">&#x0005b;131&#x0005d;</xref>. In this regard, it is noteworthy that ovarian tumors show low numbers of CD1a&#x0002b; dendritic cells; perhaps CD20&#x0002b; B cells serve as alternative antigen presenting cells in the tumor environment. This latter idea fits well with the observed co-localization of tumor-infiltrating B cells and CD8&#x0002b; T cells in EOC, as well as in medullary breast cancer, non-small cell lung cancer and cervical cancer <xref ref-type="bibr" rid="pone.0006412-Yakirevich1">&#x0005b;72&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Tamiolakis1">&#x0005b;132&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0006412-Nedergaard1">&#x0005b;134&#x0005d;</xref>.</p><p>The presence of macrophages has been associated with poor prognosis in various human cancers <xref ref-type="bibr" rid="pone.0006412-Bingle1">&#x0005b;135&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006412-Sica1">&#x0005b;136&#x0005d;</xref>. However, in accord with a prior report by Shah et. al. <xref ref-type="bibr" rid="pone.0006412-Shah1">&#x0005b;66&#x0005d;</xref>, we found no association between CD68&#x0002b; infiltrates and survival in EOC. Importantly, however, CD68 is not a perfect marker of macrophages, as it is also expressed by dendritic cells and some non-myeloid cells <xref ref-type="bibr" rid="pone.0006412-Gottfried1">&#x0005b;137&#x0005d;</xref>. Furthermore, CD68 does not distinguish between macrophages polarized towards the pro-inflammatory (M1) or tumor-promoting (M2) phenotypes. M1 macrophages have the capacity to kill tumor cells, whereas M2 macrophages promote tissue repair and angiogenesis <xref ref-type="bibr" rid="pone.0006412-Sica1">&#x0005b;136&#x0005d;</xref>. Similarly, an immunosuppressive subpopulation of macrophages has been described in EOC based on expression of the signaling molecule B7-H4 <xref ref-type="bibr" rid="pone.0006412-Kryczek2">&#x0005b;52&#x0005d;</xref>. Thus, additional functional markers may be required to fully define the role of macrophages in the immunobiology of EOC.</p><p>While this study focused on the relationship between immune infiltrates and prognosis after standard treatments, the results may also inform the design of immunotherapies for EOC. First, our findings suggest that high-grade serous tumors may be especially sensitive to T cell responses. Second, our data indicates that, in patients with residual disease, the influence of T cells may be overwhelmed by other factors. Third, the positive association between intraepithelial FoxP3&#x0002b; cells and survival reported here and previously <xref ref-type="bibr" rid="pone.0006412-Leffers1">&#x0005b;14&#x0005d;</xref> prompts a reconsideration of strategies to deplete regulatory T cells from EOC patients. And fourth, the association between intraepithelial CD20&#x0002b; cells and survival suggests the humoral immune response may play an important role in anti-tumor immunity that could be exploited therapeutically in parallel with CD8&#x0002b; T cell responses.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Study subjects</title><p>All specimens and clinical data were obtained with informed written consent under protocols approved by the Research Ethics Board of the BC Cancer Agency and the University of British Columbia. The main cohort used for this study consisted of 199 women with high-grade serous ovarian cancer seen at the BC Cancer Agency from 1984 to 2000 (OvCaRe Ovarian Tumour Bank, Vancouver, BC, Canada). Tumor tissue was obtained at the time of primary surgery prior to any other treatment. Patients had no macroscopic residual disease following surgical debulking. All patients underwent standard treatment consisting of surgery followed by standard platinum-based chemotherapy. <xref ref-type="table" rid="pone-0006412-t001">Table 1</xref> shows the general clinical characteristics of the 199-case cohort. We also analyzed a second cohort of mucinous (n&#x0200a;&#x0003d;&#x0200a;31), endometrioid (n&#x0200a;&#x0003d;&#x0200a;125) and clear cell (n&#x0200a;&#x0003d;&#x0200a;132) EOC cases. Patients in this cohort were also diagnosed from 1984 to 2000, were optimally cytoreduced, and received platinum-based chemotherapy. Finally, we analyzed a third cohort of 220 high-grade serous EOC patients categorized as extreme risk due to the presence of residual macroscopic disease. Patients in this cohort were treated from 1996 to 2000 and received platinum-based chemotherapy.</p></sec><sec id="s4b"><title>Tumor specimens</title><p>Tumor tissue was obtained during primary cytoreductive surgery, fixed in 10&#x00025; neutral buffered formalin, processed using standard procedures and embedded in paraffin. A tissue microarray (TMA) was constructed by taking duplicate 0.6 mm cores from representative regions of each tumor block after review of hematoxylin- and eosin-stained sections by a pathologist. TMAs were assembled using a Pathology Devices tissue arrayer (Westminster, MD).</p></sec><sec id="s4c"><title>Immunohistochemistry</title><p>Immunohistochemistry for CD20, CD3, CD4, CD8 and Granzyme B was performed as described in Clarke et al.<xref ref-type="bibr" rid="pone.0006412-Clarke1">&#x0005b;12&#x0005d;</xref>. The remaining unstained slides were received at the Trev and Joyce Deeley Research Centre where immunohistochemistry was performed for CD45RO, TIA-1, FoxP3, CD25, OX-40, CD56, CD57, CD1a, CD208, myeloperoxidase, CD68, COX-2, MHC Class I and MHC Class II. Following deparaffinization, the slides were placed in a Ventana Discovery XT autostainer (Ventana, Tucson, AZ) for immunohistochemical staining. Ventana's standard CC1 protocol was used for antigen retrieval. Primary antibodies are listed in <xref ref-type="table" rid="pone-0006412-t003">Table 3</xref>.</p><table-wrap id="pone-0006412-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006412.t003</object-id><label>Table 3</label><caption><title>Primary antibodies used for immunohistochemistry.</title></caption><alternatives><graphic id="pone-0006412-t003-3" xlink:href="pone.0006412.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Antigen</td><td align="left" rowspan="1" colspan="1">Clone</td><td align="left" rowspan="1" colspan="1">Supplier</td><td align="left" rowspan="1" colspan="1">Source</td><td align="left" rowspan="1" colspan="1">Concentration</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CD3</td><td align="left" rowspan="1" colspan="1">Polyclonal</td><td align="left" rowspan="1" colspan="1">Cell Marque</td><td align="left" rowspan="1" colspan="1">Rabbit</td><td align="left" rowspan="1" colspan="1">1/300</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8</td><td align="left" rowspan="1" colspan="1">C8/144C</td><td align="left" rowspan="1" colspan="1">DAKO</td><td align="left" rowspan="1" colspan="1">Rabbit</td><td align="left" rowspan="1" colspan="1">1/50</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4</td><td align="left" rowspan="1" colspan="1">4B12</td><td align="left" rowspan="1" colspan="1">Novocastra</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/50</td></tr><tr><td align="left" rowspan="1" colspan="1">Granzyme B</td><td align="left" rowspan="1" colspan="1">GrB-7</td><td align="left" rowspan="1" colspan="1">DAKO</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/25</td></tr><tr><td align="left" rowspan="1" colspan="1">CD45RO</td><td align="left" rowspan="1" colspan="1">UCHL-1</td><td align="left" rowspan="1" colspan="1">Lab Vision</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/300</td></tr><tr><td align="left" rowspan="1" colspan="1">TIA-1</td><td align="left" rowspan="1" colspan="1">TIA-1</td><td align="left" rowspan="1" colspan="1">Abcam</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/50</td></tr><tr><td align="left" rowspan="1" colspan="1">FoxP3</td><td align="left" rowspan="1" colspan="1">eBio7979</td><td align="left" rowspan="1" colspan="1">eBioscience</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/50</td></tr><tr><td align="left" rowspan="1" colspan="1">CD25</td><td align="left" rowspan="1" colspan="1">4C9</td><td align="left" rowspan="1" colspan="1">Lab Vision</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/40</td></tr><tr><td align="left" rowspan="1" colspan="1">OX-40 (CD134)</td><td align="left" rowspan="1" colspan="1">ACT35</td><td align="left" rowspan="1" colspan="1">BD Pharmingen</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/50</td></tr><tr><td align="left" rowspan="1" colspan="1">CD20</td><td align="left" rowspan="1" colspan="1">L26</td><td align="left" rowspan="1" colspan="1">DAKO</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/250</td></tr><tr><td align="left" rowspan="1" colspan="1">CD56</td><td align="left" rowspan="1" colspan="1">123C3.D5</td><td align="left" rowspan="1" colspan="1">Lab Vision</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/50</td></tr><tr><td align="left" rowspan="1" colspan="1">CD57</td><td align="left" rowspan="1" colspan="1">NK1</td><td align="left" rowspan="1" colspan="1">Lab Vision</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/200</td></tr><tr><td align="left" rowspan="1" colspan="1">CD1a</td><td align="left" rowspan="1" colspan="1">O10</td><td align="left" rowspan="1" colspan="1">Lab Vision</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/50</td></tr><tr><td align="left" rowspan="1" colspan="1">CD208</td><td align="left" rowspan="1" colspan="1">1010E1.01</td><td align="left" rowspan="1" colspan="1">Imgenix</td><td align="left" rowspan="1" colspan="1">Rat</td><td align="left" rowspan="1" colspan="1">1/50</td></tr><tr><td align="left" rowspan="1" colspan="1">Myeloperoxidase</td><td align="left" rowspan="1" colspan="1">Polyclonal, Catalogue # RB-373</td><td align="left" rowspan="1" colspan="1">Lab Vision</td><td align="left" rowspan="1" colspan="1">Rabbit</td><td align="left" rowspan="1" colspan="1">1/200</td></tr><tr><td align="left" rowspan="1" colspan="1">CD68</td><td align="left" rowspan="1" colspan="1">PG-M1</td><td align="left" rowspan="1" colspan="1">Lab Vision</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/50</td></tr><tr><td align="left" rowspan="1" colspan="1">Cyclooxygenase-2 (COX-2)</td><td align="left" rowspan="1" colspan="1">SP21</td><td align="left" rowspan="1" colspan="1">Cell Marque</td><td align="left" rowspan="1" colspan="1">Rabbit</td><td align="left" rowspan="1" colspan="1">1/10</td></tr><tr><td align="left" rowspan="1" colspan="1">MHC class I (A, B, C)</td><td align="left" rowspan="1" colspan="1">EMR8-5</td><td align="left" rowspan="1" colspan="1">MBL</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/500</td></tr><tr><td align="left" rowspan="1" colspan="1">MHC class II (DR, DP &#x00026; DQ)</td><td align="left" rowspan="1" colspan="1">CR3/43</td><td align="left" rowspan="1" colspan="1">Affinty BioReagents</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">1/50</td></tr></tbody></table></alternatives></table-wrap><p>TMAs were incubated with primary antibodies for 60 minutes at room temperature, and the appropriate cross-adsorbed, biotinylated secondary antibody (Jackson Immunoresearch, West Grove, PA) was applied for 32 minutes. Bound antibodies were detected using the DABMap kit (Ventana), counterstained with hematoxylin (Ventana), and coverslipped manually with Cytoseal-60 (Richard Allan, Kalamazoo, MI).</p></sec><sec id="s4d"><title>Histopathological analysis</title><p>Immunostained TMAs were examined by a pathologist and scored using a variety of methods depending on the marker studied. For CD20, CD8, CD4, CD45RO, TIA-1, Granzyme B, CD25, OX40, CD1a, CD56, CD57, and myeloperoxidase, only cells residing within the epithelial compartment of the tumor were counted. FoxP3 was similarly scored within the epithelium but a stromal score was also obtained. Tumors were scored as 0 (no cells), 1 (1-5 cells), 2 (6-19 cells) or 3 (20&#x0002b; cells); results were binarized as positive (IHC score 1, 2, or 3) or negative (IHC score 0). CD3 was scored as 0 (no cells present), 1 (cells present in stroma only), 2 (cells present in the epithelial compartment) or 3 (cells present in both the epithelial and stromal regions of the tumor); scores of 0 and 1 were reported as negative while a score of 2 or 3 was reported as positive. CD68 was scored as 0 (no cells present), 1 (luminal or stromal cells), 2 (scattered, &#x0003c;20 intraepithelial cells), or 3 (&#x0003e;20 intraepithelial cells), results were binarized in the same manner as CD3. COX-2 was scored as 0 (negative), 1 (equivocal, 0-1&#x00025;), 2 (patchy, &#x0003e;1&#x00025; to 50&#x00025;) or 3 (diffuse, &#x0003e;50&#x00025;) scores of 0 and 1 were reported as negative and scores of 2 or 3 were reported as positive. For MHC class I and II, samples were scored as 0 (negative), 1 (focal, &#x0003c;10&#x00025;), 2 (patchy, 10-50&#x00025;) or 3 (diffuse, &#x0003e;50&#x00025;). Scores of 0, 1 or 2 were reported as negative and scores of 3 were reported as positive.</p></sec><sec id="s4e"><title>Statistical analysis</title><p>Statistical analysis was performed using JMP statistical software (v7.0) (SAS Institute, Cary, NC). Univariate analysis was carried out using the Chi-Squared statistic. The log-rank test was used to compare Kaplan-Meier curves. <italic>p</italic>-values less than 0.05 were considered significant.</p></sec></sec></body><back><ack><p>We thank Jennifer Santos, Erika Mehl, Rob Grigor, and members of the Deeley Research Centre for assistance and advice.</p></ack><ref-list><title>References</title><ref id="pone.0006412-Ozols1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozols</surname><given-names>RF</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Greer</surname><given-names>BE</given-names></name><name><surname>Fowler</surname><given-names>JM</given-names></name><name><surname>Clarke-Pearson</surname><given-names>D</given-names></name><etal/></person-group><year>2003</year><article-title>Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.</article-title><source>J Clin Oncol</source><volume>21</volume><fpage>3194</fpage><lpage>3200</lpage><pub-id pub-id-type="pmid">12860964</pub-id></mixed-citation></ref><ref id="pone.0006412-duBois1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>du Bois</surname><given-names>A</given-names></name><name><surname>Luck</surname><given-names>HJ</given-names></name><name><surname>Meier</surname><given-names>W</given-names></name><name><surname>Adams</surname><given-names>HP</given-names></name><name><surname>Mobus</surname><given-names>V</given-names></name><etal/></person-group><year>2003</year><article-title>A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.</article-title><source>J Natl Cancer Inst</source><volume>95</volume><fpage>1320</fpage><lpage>1329</lpage><pub-id pub-id-type="pmid">12953086</pub-id></mixed-citation></ref><ref id="pone.0006412-Holschneider1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holschneider</surname><given-names>CH</given-names></name><name><surname>Berek</surname><given-names>JS</given-names></name></person-group><year>2000</year><article-title>Ovarian cancer: epidemiology, biology, and prognostic factors.</article-title><source>Semin Surg Oncol</source><volume>19</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">10883018</pub-id></mixed-citation></ref><ref id="pone.0006412-Ozols2"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozols</surname><given-names>RF</given-names></name></person-group><year>2000</year><article-title>Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.</article-title><source>Semin Oncol</source><volume>27</volume><fpage>47</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">10952127</pub-id></mixed-citation></ref><ref id="pone.0006412-Zhang1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Massobrio</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.</article-title><source>N Engl J Med</source><volume>348</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">12529460</pub-id></mixed-citation></ref><ref id="pone.0006412-Raspollini1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raspollini</surname><given-names>MR</given-names></name><name><surname>Castiglione</surname><given-names>F</given-names></name><name><surname>Rossi Degl'innocenti</surname><given-names>D</given-names></name><name><surname>Amunni</surname><given-names>G</given-names></name><name><surname>Villanucci</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma.</article-title><source>Ann Oncol</source><volume>16</volume><fpage>590</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">15699022</pub-id></mixed-citation></ref><ref id="pone.0006412-Tomsova1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomsova</surname><given-names>M</given-names></name><name><surname>Melichar</surname><given-names>B</given-names></name><name><surname>Sedlakova</surname><given-names>I</given-names></name><name><surname>Steiner</surname><given-names>I</given-names></name></person-group><year>2008</year><article-title>Prognostic significance of CD3&#x0002b; tumor-infiltrating lymphocytes in ovarian carcinoma.</article-title><source>Gynecol Oncol</source><volume>108</volume><fpage>415</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">18037158</pub-id></mixed-citation></ref><ref id="pone.0006412-Nelson1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>BH</given-names></name></person-group><year>2008</year><article-title>The impact of T-cell immunity on ovarian cancer outcomes.</article-title><source>Immunol Rev</source><volume>222</volume><fpage>101</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">18363996</pub-id></mixed-citation></ref><ref id="pone.0006412-Gimotty1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Alagkiozidis</surname><given-names>I</given-names></name><name><surname>Cadungog</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Immune prognostic factors in ovarian cancer: lessons from translational research.</article-title><source>Dis Markers</source><volume>23</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">18057527</pub-id></mixed-citation></ref><ref id="pone.0006412-Sato1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>E</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Bundy</surname><given-names>B</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name><etal/></person-group><year>2005</year><article-title>Intraepithelial CD8&#x0002b; tumor-infiltrating lymphocytes and a high CD8&#x0002b;/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><fpage>18538</fpage><lpage>18543</lpage><pub-id pub-id-type="pmid">16344461</pub-id></mixed-citation></ref><ref id="pone.0006412-Hamanishi1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamanishi</surname><given-names>J</given-names></name><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Iwasaki</surname><given-names>M</given-names></name><name><surname>Okazaki</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><etal/></person-group><year>2007</year><article-title>Programmed cell death 1 ligand 1 and tumor-infiltrating CD8&#x0002b; T lymphocytes are prognostic factors of human ovarian cancer.</article-title><source>Proc Natl Acad Sci U S A</source><volume>104</volume><fpage>3360</fpage><lpage>3365</lpage><pub-id pub-id-type="pmid">17360651</pub-id></mixed-citation></ref><ref id="pone.0006412-Clarke1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>B</given-names></name><name><surname>Tinker</surname><given-names>AV</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Subramanian</surname><given-names>S</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><etal/></person-group><year>2009</year><article-title>Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.</article-title><source>Mod Pathol</source><volume>22</volume><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">19060844</pub-id></mixed-citation></ref><ref id="pone.0006412-Liu1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Yagi</surname><given-names>H</given-names></name><etal/></person-group><year>2009</year><article-title>Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression.</article-title><source>Mod Pathol</source><volume>22</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">18997734</pub-id></mixed-citation></ref><ref id="pone.0006412-Leffers1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leffers</surname><given-names>N</given-names></name><name><surname>Gooden</surname><given-names>MJ</given-names></name><name><surname>de Jong</surname><given-names>RA</given-names></name><name><surname>Hoogeboom</surname><given-names>BN</given-names></name><name><surname>ten Hoor</surname><given-names>KA</given-names></name><etal/></person-group><year>2009</year><article-title>Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.</article-title><source>Cancer Immunol Immunother</source><volume>58</volume><fpage>449</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">18791714</pub-id></mixed-citation></ref><ref id="pone.0006412-Callahan1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callahan</surname><given-names>MJ</given-names></name><name><surname>Nagymanyoki</surname><given-names>Z</given-names></name><name><surname>Bonome</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>ME</given-names></name><name><surname>Litkouhi</surname><given-names>B</given-names></name><etal/></person-group><year>2008</year><article-title>Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>7667</fpage><lpage>7673</lpage><pub-id pub-id-type="pmid">19047092</pub-id></mixed-citation></ref><ref id="pone.0006412-Matsushita1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>N</given-names></name><name><surname>Ghazizadeh</surname><given-names>M</given-names></name><name><surname>Konishi</surname><given-names>H</given-names></name><name><surname>Araki</surname><given-names>T</given-names></name></person-group><year>2003</year><article-title>Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes.</article-title><source>J Nippon Med Sch</source><volume>70</volume><fpage>40</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">12646975</pub-id></mixed-citation></ref><ref id="pone.0006412-Han1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>LY</given-names></name><name><surname>Fletcher</surname><given-names>MS</given-names></name><name><surname>Urbauer</surname><given-names>DL</given-names></name><name><surname>Mueller</surname><given-names>P</given-names></name><name><surname>Landen</surname><given-names>CN</given-names></name><etal/></person-group><year>2008</year><article-title>HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma.</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>3372</fpage><lpage>3379</lpage><pub-id pub-id-type="pmid">18519766</pub-id></mixed-citation></ref><ref id="pone.0006412-Marth1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marth</surname><given-names>C</given-names></name><name><surname>Fiegl</surname><given-names>H</given-names></name><name><surname>Zeimet</surname><given-names>AG</given-names></name><name><surname>Muller-Holzner</surname><given-names>E</given-names></name><name><surname>Deibl</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>Interferon-gamma expression is an independent prognostic factor in ovarian cancer.</article-title><source>Am J Obstet Gynecol</source><volume>191</volume><fpage>1598</fpage><lpage>1605</lpage><pub-id pub-id-type="pmid">15547530</pub-id></mixed-citation></ref><ref id="pone.0006412-Kusuda1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusuda</surname><given-names>T</given-names></name><name><surname>Shigemasa</surname><given-names>K</given-names></name><name><surname>Arihiro</surname><given-names>K</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Nagai</surname><given-names>N</given-names></name><etal/></person-group><year>2005</year><article-title>Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.</article-title><source>Oncol Rep</source><volume>13</volume><fpage>1153</fpage><lpage>1158</lpage><pub-id pub-id-type="pmid">15870936</pub-id></mixed-citation></ref><ref id="pone.0006412-Duncan1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>TJ</given-names></name><name><surname>Rolland</surname><given-names>P</given-names></name><name><surname>Deen</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>IV</given-names></name><name><surname>Liu</surname><given-names>DT</given-names></name><etal/></person-group><year>2007</year><article-title>Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer.</article-title><source>Clin Cancer Res</source><volume>13</volume><fpage>4139</fpage><lpage>4145</lpage><pub-id pub-id-type="pmid">17634541</pub-id></mixed-citation></ref><ref id="pone.0006412-Zeimet1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeimet</surname><given-names>AG</given-names></name><name><surname>Reimer</surname><given-names>D</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Fiegl</surname><given-names>H</given-names></name><name><surname>Concin</surname><given-names>N</given-names></name><etal/></person-group><year>2008</year><article-title>Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.</article-title><source>Int J Cancer</source></mixed-citation></ref><ref id="pone.0006412-Akahiro1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akahiro</surname><given-names>J</given-names></name><name><surname>Konno</surname><given-names>R</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Okamura</surname><given-names>K</given-names></name><name><surname>Yaegashi</surname><given-names>N</given-names></name></person-group><year>2004</year><article-title>Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma.</article-title><source>Int J Clin Oncol</source><volume>9</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15162825</pub-id></mixed-citation></ref><ref id="pone.0006412-Bamias1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamias</surname><given-names>A</given-names></name><name><surname>Tsiatas</surname><given-names>ML</given-names></name><name><surname>Kafantari</surname><given-names>E</given-names></name><name><surname>Liakou</surname><given-names>C</given-names></name><name><surname>Rodolakis</surname><given-names>A</given-names></name><etal/></person-group><year>2007</year><article-title>Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3(&#x0002b;)CD56(&#x0002b;) cells with platinum resistance.</article-title><source>Gynecol Oncol</source></mixed-citation></ref><ref id="pone.0006412-Rolland1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolland</surname><given-names>P</given-names></name><name><surname>Deen</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>I</given-names></name><name><surname>Durrant</surname><given-names>L</given-names></name><name><surname>Spendlove</surname><given-names>I</given-names></name></person-group><year>2007</year><article-title>Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.</article-title><source>Clin Cancer Res</source><volume>13</volume><fpage>3591</fpage><lpage>3596</lpage><pub-id pub-id-type="pmid">17575223</pub-id></mixed-citation></ref><ref id="pone.0006412-Moore1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>DH</given-names></name><name><surname>Fowler</surname><given-names>WC</given-names><suffix>Jr</suffix></name><name><surname>Olafsson</surname><given-names>K</given-names></name></person-group><year>1990</year><article-title>Class I histocompatibility antigen expression: a prognostic factor for aneuploid ovarian cancers.</article-title><volume>38</volume><fpage>458</fpage><lpage>461</lpage></mixed-citation></ref><ref id="pone.0006412-Leffers2"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leffers</surname><given-names>N</given-names></name><name><surname>Lambeck</surname><given-names>AJ</given-names></name><name><surname>de Graeff</surname><given-names>P</given-names></name><name><surname>Bijlsma</surname><given-names>AY</given-names></name><name><surname>Daemen</surname><given-names>T</given-names></name><etal/></person-group><year>2008</year><article-title>Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.</article-title><source>Gynecol Oncol</source><volume>110</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">18571704</pub-id></mixed-citation></ref><ref id="pone.0006412-Wolf1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Wolf</surname><given-names>AM</given-names></name><name><surname>Rumpold</surname><given-names>H</given-names></name><name><surname>Fiegl</surname><given-names>H</given-names></name><name><surname>Zeimet</surname><given-names>AG</given-names></name><etal/></person-group><year>2005</year><article-title>The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.</article-title><source>Clin Cancer Res</source><volume>11</volume><fpage>8326</fpage><lpage>8331</lpage><pub-id pub-id-type="pmid">16322292</pub-id></mixed-citation></ref><ref id="pone.0006412-Curiel1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><etal/></person-group><year>2004</year><article-title>Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.</article-title><source>Nat Med</source><volume>10</volume><fpage>942</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">15322536</pub-id></mixed-citation></ref><ref id="pone.0006412-Woo1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>EY</given-names></name><name><surname>Chu</surname><given-names>CS</given-names></name><name><surname>Goletz</surname><given-names>TJ</given-names></name><name><surname>Schlienger</surname><given-names>K</given-names></name><name><surname>Yeh</surname><given-names>H</given-names></name><etal/></person-group><year>2001</year><article-title>Regulatory CD4(&#x0002b;)CD25(&#x0002b;) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.</article-title><source>Cancer Res</source><volume>61</volume><fpage>4766</fpage><lpage>4772</lpage><pub-id pub-id-type="pmid">11406550</pub-id></mixed-citation></ref><ref id="pone.0006412-Miyara1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyara</surname><given-names>M</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><year>2007</year><article-title>Natural regulatory T cells: mechanisms of suppression.</article-title><source>Trends Mol Med</source><volume>13</volume><fpage>108</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">17257897</pub-id></mixed-citation></ref><ref id="pone.0006412-Piccirillo1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccirillo</surname><given-names>CA</given-names></name></person-group><year>2008</year><article-title>Regulatory T cells in health and disease.</article-title><source>Cytokine</source><volume>43</volume><fpage>395</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">18722786</pub-id></mixed-citation></ref><ref id="pone.0006412-Kryczek1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Myers</surname><given-names>L</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><etal/></person-group><year>2007</year><article-title>Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.</article-title><source>Cancer Res</source><volume>67</volume><fpage>8900</fpage><lpage>8905</lpage><pub-id pub-id-type="pmid">17875732</pub-id></mixed-citation></ref><ref id="pone.0006412-Salama1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>P</given-names></name><name><surname>Phillips</surname><given-names>M</given-names></name><name><surname>Grieu</surname><given-names>F</given-names></name><name><surname>Morris</surname><given-names>M</given-names></name><name><surname>Zeps</surname><given-names>N</given-names></name><etal/></person-group><year>2009</year><article-title>Tumor-infiltrating FOXP3&#x0002b; T regulatory cells show strong prognostic significance in colorectal cancer.</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>186</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">19064967</pub-id></mixed-citation></ref><ref id="pone.0006412-deJong1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>Koster</surname><given-names>A</given-names></name><name><surname>Hagenbeek</surname><given-names>A</given-names></name><name><surname>Raemaekers</surname><given-names>J</given-names></name><name><surname>Veldhuizen</surname><given-names>D</given-names></name><etal/></person-group><year>2009</year><article-title>Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.</article-title><source>Haematologica</source><volume>94</volume><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">19059937</pub-id></mixed-citation></ref><ref id="pone.0006412-Ke1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>IH</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><year>2008</year><article-title>Roles of CD4&#x0002b;CD25(high) FOXP3&#x0002b; Tregs in lymphomas and tumors are complex.</article-title><source>Front Biosci</source><volume>13</volume><fpage>3986</fpage><lpage>4001</lpage><pub-id pub-id-type="pmid">18508492</pub-id></mixed-citation></ref><ref id="pone.0006412-Carreras1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carreras</surname><given-names>J</given-names></name><name><surname>Lopez-Guillermo</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>BC</given-names></name><name><surname>Colomo</surname><given-names>L</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.</article-title><source>Blood</source><volume>108</volume><fpage>2957</fpage><lpage>2964</lpage><pub-id pub-id-type="pmid">16825494</pub-id></mixed-citation></ref><ref id="pone.0006412-Erdman1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdman</surname><given-names>SE</given-names></name><name><surname>Sohn</surname><given-names>JJ</given-names></name><name><surname>Rao</surname><given-names>VP</given-names></name><name><surname>Nambiar</surname><given-names>PR</given-names></name><name><surname>Ge</surname><given-names>Z</given-names></name><etal/></person-group><year>2005</year><article-title>CD4&#x0002b;CD25&#x0002b; regulatory lymphocytes induce regression of intestinal tumors in ApcMin/&#x0002b; mice.</article-title><source>Cancer Res</source><volume>65</volume><fpage>3998</fpage><lpage>4004</lpage><pub-id pub-id-type="pmid">15899788</pub-id></mixed-citation></ref><ref id="pone.0006412-Lund1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>JM</given-names></name><name><surname>Hsing</surname><given-names>L</given-names></name><name><surname>Pham</surname><given-names>TT</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year>2008</year><article-title>Coordination of early protective immunity to viral infection by regulatory T cells.</article-title><source>Science</source><volume>320</volume><fpage>1220</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">18436744</pub-id></mixed-citation></ref><ref id="pone.0006412-Mahnke1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahnke</surname><given-names>K</given-names></name><name><surname>Schonfeld</surname><given-names>K</given-names></name><name><surname>Fondel</surname><given-names>S</given-names></name><name><surname>Ring</surname><given-names>S</given-names></name><name><surname>Karakhanova</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Depletion of CD4(&#x0002b;)CD25(&#x0002b;) human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.</article-title><source>Int J Cancer</source><volume>120</volume><fpage>2723</fpage><lpage>2733</lpage><pub-id pub-id-type="pmid">17315189</pub-id></mixed-citation></ref><ref id="pone.0006412-Morse1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morse</surname><given-names>MA</given-names></name><name><surname>Hobeika</surname><given-names>AC</given-names></name><name><surname>Osada</surname><given-names>T</given-names></name><name><surname>Serra</surname><given-names>D</given-names></name><name><surname>Niedzwiecki</surname><given-names>D</given-names></name><etal/></person-group><year>2008</year><article-title>Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.</article-title><source>Blood</source><volume>112</volume><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">18519811</pub-id></mixed-citation></ref><ref id="pone.0006412-Powell1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>DJ</given-names><suffix>Jr</suffix></name><name><surname>Attia</surname><given-names>P</given-names></name><name><surname>Ghetie</surname><given-names>V</given-names></name><name><surname>Schindler</surname><given-names>J</given-names></name><name><surname>Vitetta</surname><given-names>ES</given-names></name><etal/></person-group><year>2008</year><article-title>Partial reduction of human FOXP3&#x0002b; CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.</article-title><source>J Immunother</source><volume>31</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">18481388</pub-id></mixed-citation></ref><ref id="pone.0006412-Powell2"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>DJ</given-names><suffix>Jr</suffix></name><name><surname>Felipe-Silva</surname><given-names>A</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Ahmadzadeh</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.</article-title><source>J Immunol</source><volume>179</volume><fpage>4919</fpage><lpage>4928</lpage><pub-id pub-id-type="pmid">17878392</pub-id></mixed-citation></ref><ref id="pone.0006412-Dannull1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dannull</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Rizzieri</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>BK</given-names></name><name><surname>Coleman</surname><given-names>D</given-names></name><etal/></person-group><year>2005</year><article-title>Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.</article-title><source>J Clin Invest</source><volume>115</volume><fpage>3623</fpage><lpage>3633</lpage><pub-id pub-id-type="pmid">16308572</pub-id></mixed-citation></ref><ref id="pone.0006412-Rasku1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasku</surname><given-names>MA</given-names></name><name><surname>Clem</surname><given-names>AL</given-names></name><name><surname>Telang</surname><given-names>S</given-names></name><name><surname>Taft</surname><given-names>B</given-names></name><name><surname>Gettings</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>Transient T cell depletion causes regression of melanoma metastases.</article-title><source>J Transl Med</source><volume>6</volume><fpage>12</fpage><pub-id pub-id-type="pmid">18334033</pub-id></mixed-citation></ref><ref id="pone.0006412-Barnett1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>B</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Curiel</surname><given-names>TJ</given-names></name></person-group><year>2005</year><article-title>Regulatory T cells in ovarian cancer: biology and therapeutic potential.</article-title><source>Am J Reprod Immunol</source><volume>54</volume><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">16305662</pub-id></mixed-citation></ref><ref id="pone.0006412-Wei1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><etal/></person-group><year>2005</year><article-title>Plasmacytoid dendritic cells induce CD8&#x0002b; regulatory T cells in human ovarian carcinoma.</article-title><source>Cancer Res</source><volume>65</volume><fpage>5020</fpage><lpage>5026</lpage><pub-id pub-id-type="pmid">15958543</pub-id></mixed-citation></ref><ref id="pone.0006412-Zou1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Machelon</surname><given-names>V</given-names></name><name><surname>Coulomb-L'Hermin</surname><given-names>A</given-names></name><name><surname>Borvak</surname><given-names>J</given-names></name><name><surname>Nome</surname><given-names>F</given-names></name><etal/></person-group><year>2001</year><article-title>Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.</article-title><source>Nat Med</source><volume>7</volume><fpage>1339</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">11726975</pub-id></mixed-citation></ref><ref id="pone.0006412-Curiel2"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><etal/></person-group><year>2003</year><article-title>Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.</article-title><source>Nat Med</source><volume>9</volume><fpage>562</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">12704383</pub-id></mixed-citation></ref><ref id="pone.0006412-Duluc1"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duluc</surname><given-names>D</given-names></name><name><surname>Delneste</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>F</given-names></name><name><surname>Moles</surname><given-names>MP</given-names></name><name><surname>Grimaud</surname><given-names>L</given-names></name><etal/></person-group><year>2007</year><article-title>Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated-macrophage-like cells.</article-title><source>Blood</source></mixed-citation></ref><ref id="pone.0006412-Hagemann1"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagemann</surname><given-names>T</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Burke</surname><given-names>F</given-names></name><name><surname>Kulbe</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>NF</given-names></name><etal/></person-group><year>2006</year><article-title>Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.</article-title><source>J Immunol</source><volume>176</volume><fpage>5023</fpage><lpage>5032</lpage><pub-id pub-id-type="pmid">16585599</pub-id></mixed-citation></ref><ref id="pone.0006412-Loercher1"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loercher</surname><given-names>AE</given-names></name><name><surname>Nash</surname><given-names>MA</given-names></name><name><surname>Kavanagh</surname><given-names>JJ</given-names></name><name><surname>Platsoucas</surname><given-names>CD</given-names></name><name><surname>Freedman</surname><given-names>RS</given-names></name></person-group><year>1999</year><article-title>Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.</article-title><source>J Immunol</source><volume>163</volume><fpage>6251</fpage><lpage>6260</lpage><pub-id pub-id-type="pmid">10570318</pub-id></mixed-citation></ref><ref id="pone.0006412-Kryczek2"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Rodriguez</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><etal/></person-group><year>2006</year><article-title>B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.</article-title><source>J Exp Med</source><volume>203</volume><fpage>871</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">16606666</pub-id></mixed-citation></ref><ref id="pone.0006412-Denkert1"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denkert</surname><given-names>C</given-names></name><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Pest</surname><given-names>S</given-names></name><name><surname>Koch</surname><given-names>I</given-names></name><name><surname>Berger</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.</article-title><source>Am J Pathol</source><volume>160</volume><fpage>893</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">11891188</pub-id></mixed-citation></ref><ref id="pone.0006412-Kobel1"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Kalloger</surname><given-names>SE</given-names></name><name><surname>Boyd</surname><given-names>N</given-names></name><name><surname>McKinney</surname><given-names>S</given-names></name><name><surname>Mehl</surname><given-names>E</given-names></name><etal/></person-group><year>2008</year><article-title>Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.</article-title><source>PLoS Med</source><volume>5</volume><fpage>e232</fpage><pub-id pub-id-type="pmid">19053170</pub-id></mixed-citation></ref><ref id="pone.0006412-Gilks1"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilks</surname><given-names>CB</given-names></name><name><surname>Ionescu</surname><given-names>DN</given-names></name><name><surname>Kalloger</surname><given-names>SE</given-names></name><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Irving</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><article-title>Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human Pathology In press.</article-title></mixed-citation></ref><ref id="pone.0006412-Brenchley1"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Ambrozak</surname><given-names>DR</given-names></name><name><surname>Chatterji</surname><given-names>M</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><etal/></person-group><year>2002</year><article-title>Expansion of activated human naive T-cells precedes effector function.</article-title><source>Clin Exp Immunol</source><volume>130</volume><fpage>432</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">12452833</pub-id></mixed-citation></ref><ref id="pone.0006412-Weinberg1"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>AD</given-names></name></person-group><year>2002</year><article-title>OX40: targeted immunotherapy&#x02013;implications for tempering autoimmunity and enhancing vaccines.</article-title><source>Trends Immunol</source><volume>23</volume><fpage>102</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">11929124</pub-id></mixed-citation></ref><ref id="pone.0006412-Pipkin1"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pipkin</surname><given-names>ME</given-names></name><name><surname>Lieberman</surname><given-names>J</given-names></name></person-group><year>2007</year><article-title>Delivering the kiss of death: progress on understanding how perforin works.</article-title><source>Curr Opin Immunol</source><volume>19</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">17433871</pub-id></mixed-citation></ref><ref id="pone.0006412-Kawakami1"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>A</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Streuli</surname><given-names>M</given-names></name><name><surname>Schlossman</surname><given-names>SF</given-names></name><etal/></person-group><year>1992</year><article-title>Identification and functional characterization of a TIA-1-related nucleolysin.</article-title><source>Proc Natl Acad Sci U S A</source><volume>89</volume><fpage>8681</fpage><lpage>8685</lpage><pub-id pub-id-type="pmid">1326761</pub-id></mixed-citation></ref><ref id="pone.0006412-Kanavaros1"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanavaros</surname><given-names>P</given-names></name><name><surname>Boulland</surname><given-names>ML</given-names></name><name><surname>Petit</surname><given-names>B</given-names></name><name><surname>Arnulf</surname><given-names>B</given-names></name><name><surname>Gaulard</surname><given-names>P</given-names></name></person-group><year>2000</year><article-title>Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.</article-title><source>Leuk Lymphoma</source><volume>38</volume><fpage>317</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">10830738</pub-id></mixed-citation></ref><ref id="pone.0006412-Ziegler1"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>SF</given-names></name></person-group><year>2007</year><article-title>FOXP3: not just for regulatory T cells anymore.</article-title><source>Eur J Immunol</source><volume>37</volume><fpage>21</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">17183612</pub-id></mixed-citation></ref><ref id="pone.0006412-Zou2"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>W</given-names></name></person-group><year>2006</year><article-title>Regulatory T cells, tumour immunity and immunotherapy.</article-title><source>Nat Rev Immunol</source><volume>6</volume><fpage>295</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">16557261</pub-id></mixed-citation></ref><ref id="pone.0006412-Edwards1"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>JC</given-names></name><name><surname>Cambridge</surname><given-names>G</given-names></name></person-group><year>2006</year><article-title>B-cell targeting in rheumatoid arthritis and other autoimmune diseases.</article-title><source>Nat Rev Immunol</source><volume>6</volume><fpage>394</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">16622478</pub-id></mixed-citation></ref><ref id="pone.0006412-Ahmadi1"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadi</surname><given-names>M</given-names></name><name><surname>Emery</surname><given-names>DC</given-names></name><name><surname>Morgan</surname><given-names>DJ</given-names></name></person-group><year>2008</year><article-title>Prevention of both direct and cross-priming of antitumor CD8&#x0002b; T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo.</article-title><source>Cancer Res</source><volume>68</volume><fpage>7520</fpage><lpage>7529</lpage><pub-id pub-id-type="pmid">18794140</pub-id></mixed-citation></ref><ref id="pone.0006412-Lang1"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>S</given-names></name><name><surname>Tiwari</surname><given-names>S</given-names></name><name><surname>Andratschke</surname><given-names>M</given-names></name><name><surname>Loehr</surname><given-names>I</given-names></name><name><surname>Lauffer</surname><given-names>L</given-names></name><etal/></person-group><year>2007</year><article-title>Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.</article-title><source>Cancer Immunol Immunother</source><volume>56</volume><fpage>1645</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">17387473</pub-id></mixed-citation></ref><ref id="pone.0006412-Shah1"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>CA</given-names></name><name><surname>Allison</surname><given-names>KH</given-names></name><name><surname>Garcia</surname><given-names>RL</given-names></name><name><surname>Gray</surname><given-names>HJ</given-names></name><name><surname>Goff</surname><given-names>BA</given-names></name><etal/></person-group><year>2008</year><article-title>Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.</article-title><source>Gynecol Oncol</source><volume>109</volume><fpage>215</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">18314181</pub-id></mixed-citation></ref><ref id="pone.0006412-Kooi1"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kooi</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>HZ</given-names></name><name><surname>Patenia</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>CL</given-names></name><name><surname>Platsoucas</surname><given-names>CD</given-names></name><etal/></person-group><year>1996</year><article-title>HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.</article-title><volume>174</volume><fpage>116</fpage><lpage>128</lpage></mixed-citation></ref><ref id="pone.0006412-Buckanovich1"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckanovich</surname><given-names>RJ</given-names></name><name><surname>Facciabene</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Benencia</surname><given-names>F</given-names></name><name><surname>Sasaroli</surname><given-names>D</given-names></name><etal/></person-group><year>2008</year><article-title>Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.</article-title><source>Nat Med</source><volume>14</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">18157142</pub-id></mixed-citation></ref><ref id="pone.0006412-Negus1"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negus</surname><given-names>RP</given-names></name><name><surname>Stamp</surname><given-names>GW</given-names></name><name><surname>Hadley</surname><given-names>J</given-names></name><name><surname>Balkwill</surname><given-names>FR</given-names></name></person-group><year>1997</year><article-title>Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.</article-title><source>Am J Pathol</source><volume>150</volume><fpage>1723</fpage><lpage>1734</lpage><pub-id pub-id-type="pmid">9137096</pub-id></mixed-citation></ref><ref id="pone.0006412-Tothill1"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tothill</surname><given-names>RW</given-names></name><name><surname>Tinker</surname><given-names>AV</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><etal/></person-group><year>2008</year><article-title>Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>5198</fpage><lpage>5208</lpage><pub-id pub-id-type="pmid">18698038</pub-id></mixed-citation></ref><ref id="pone.0006412-Kuroda1"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuroda</surname><given-names>H</given-names></name><name><surname>Tamaru</surname><given-names>J</given-names></name><name><surname>Sakamoto</surname><given-names>G</given-names></name><name><surname>Ohnisi</surname><given-names>K</given-names></name><name><surname>Itoyama</surname><given-names>S</given-names></name></person-group><year>2005</year><article-title>Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast.</article-title><source>Virchows Arch</source><volume>446</volume><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15660281</pub-id></mixed-citation></ref><ref id="pone.0006412-Yakirevich1"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yakirevich</surname><given-names>E</given-names></name><name><surname>Izhak</surname><given-names>OB</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Kovacs</surname><given-names>ZG</given-names></name><name><surname>Resnick</surname><given-names>MB</given-names></name></person-group><year>1999</year><article-title>Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast.</article-title><source>Mod Pathol</source><volume>12</volume><fpage>1050</fpage><lpage>1056</lpage><pub-id pub-id-type="pmid">10574602</pub-id></mixed-citation></ref><ref id="pone.0006412-Lyle1"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyle</surname><given-names>S</given-names></name><name><surname>Salhany</surname><given-names>KE</given-names></name><name><surname>Elder</surname><given-names>DE</given-names></name><name><surname>Yakirevich</surname><given-names>E</given-names></name><name><surname>Izhak</surname><given-names>OB</given-names></name><etal/></person-group><year>2000</year><article-title>TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas.</article-title></mixed-citation></ref><ref id="pone.0006412-Hasselblom1"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasselblom</surname><given-names>S</given-names></name><name><surname>Sigurdadottir</surname><given-names>M</given-names></name><name><surname>Hansson</surname><given-names>U</given-names></name><name><surname>Nilsson-Ehle</surname><given-names>H</given-names></name><name><surname>Ridell</surname><given-names>B</given-names></name><etal/></person-group><year>2007</year><article-title>The number of tumour-infiltrating TIA-1&#x0002b; cytotoxic T cells but not FOXP3&#x0002b; regulatory T cells predicts outcome in diffuse large B-cell lymphoma.</article-title><source>Br J Haematol</source><volume>137</volume><fpage>364</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">17456059</pub-id></mixed-citation></ref><ref id="pone.0006412-Chetaille1"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chetaille</surname><given-names>B</given-names></name><name><surname>Bertucci</surname><given-names>F</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Esterni</surname><given-names>B</given-names></name><name><surname>Stamatoullas</surname><given-names>A</given-names></name><etal/></person-group><year>2009</year><article-title>Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.</article-title></mixed-citation></ref><ref id="pone.0006412-Asano1"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>N</given-names></name><name><surname>Oshiro</surname><given-names>A</given-names></name><name><surname>Matsuo</surname><given-names>K</given-names></name><name><surname>Kagami</surname><given-names>Y</given-names></name><name><surname>Ishida</surname><given-names>F</given-names></name><etal/></person-group><year>2006</year><article-title>Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study.</article-title></mixed-citation></ref><ref id="pone.0006412-AlvaroNaranjo1"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvaro-Naranjo</surname><given-names>T</given-names></name><name><surname>Lejeune</surname><given-names>M</given-names></name><name><surname>Salvado-Usach</surname><given-names>MT</given-names></name><name><surname>Bosch-Princep</surname><given-names>R</given-names></name><name><surname>Reverter-Branchat</surname><given-names>G</given-names></name><etal/></person-group><year>2005</year><article-title>Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients.</article-title></mixed-citation></ref><ref id="pone.0006412-Alvaro1"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvaro</surname><given-names>T</given-names></name><name><surname>Lejeune</surname><given-names>M</given-names></name><name><surname>Salvado</surname><given-names>MT</given-names></name><name><surname>Bosch</surname><given-names>R</given-names></name><name><surname>Garcia</surname><given-names>JF</given-names></name><etal/></person-group><year>2005</year><article-title>Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.</article-title></mixed-citation></ref><ref id="pone.0006412-Anderson1"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>P</given-names></name><name><surname>Phillips</surname><given-names>K</given-names></name><name><surname>Stoecklin</surname><given-names>G</given-names></name><name><surname>Kedersha</surname><given-names>N</given-names></name></person-group><year>2004</year><article-title>Post-transcriptional regulation of proinflammatory proteins.</article-title><source>J Leukoc Biol</source><volume>76</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15075353</pub-id></mixed-citation></ref><ref id="pone.0006412-Woo2"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>YL</given-names></name><name><surname>Sterling</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>R</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name><name><surname>Coleman</surname><given-names>N</given-names></name><etal/></person-group><year>2008</year><article-title>FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies.</article-title><source>J Clin Pathol</source><volume>61</volume><fpage>969</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">18413654</pub-id></mixed-citation></ref><ref id="pone.0006412-Mizukami1"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizukami</surname><given-names>Y</given-names></name><name><surname>Kono</surname><given-names>K</given-names></name><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><name><surname>Akaike</surname><given-names>H</given-names></name><name><surname>Kamimura</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>Localisation pattern of Foxp3&#x0002b; regulatory T cells is associated with clinical behaviour in gastric cancer.</article-title><source>Br J Cancer</source><volume>98</volume><fpage>148</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">18087278</pub-id></mixed-citation></ref><ref id="pone.0006412-Ahmadzadeh1"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadzadeh</surname><given-names>M</given-names></name><name><surname>Felipe-Silva</surname><given-names>A</given-names></name><name><surname>Heemskerk</surname><given-names>B</given-names></name><name><surname>Powell</surname><given-names>DJ</given-names><suffix>Jr</suffix></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><etal/></person-group><year>2008</year><article-title>FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.</article-title><source>Blood</source><volume>112</volume><fpage>4953</fpage><lpage>4960</lpage><pub-id pub-id-type="pmid">18820132</pub-id></mixed-citation></ref><ref id="pone.0006412-Kryczek3"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Shu</surname><given-names>X</given-names></name><etal/></person-group><year>2009</year><article-title>FOXP3 defines regulatory T cells in human tumor and autoimmune disease.</article-title><source>Cancer Res</source><volume>69</volume><fpage>3995</fpage><lpage>4000</lpage><pub-id pub-id-type="pmid">19383912</pub-id></mixed-citation></ref><ref id="pone.0006412-Karanikas1"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karanikas</surname><given-names>V</given-names></name><name><surname>Speletas</surname><given-names>M</given-names></name><name><surname>Zamanakou</surname><given-names>M</given-names></name><name><surname>Kalala</surname><given-names>F</given-names></name><name><surname>Loules</surname><given-names>G</given-names></name><etal/></person-group><year>2008</year><article-title>Foxp3 expression in human cancer cells.</article-title><source>J Transl Med</source><volume>6</volume><fpage>19</fpage><pub-id pub-id-type="pmid">18430198</pub-id></mixed-citation></ref><ref id="pone.0006412-Hinz1"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinz</surname><given-names>S</given-names></name><name><surname>Pagerols-Raluy</surname><given-names>L</given-names></name><name><surname>Oberg</surname><given-names>HH</given-names></name><name><surname>Ammerpohl</surname><given-names>O</given-names></name><name><surname>Grussel</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.</article-title><source>Cancer Res</source><volume>67</volume><fpage>8344</fpage><lpage>8350</lpage><pub-id pub-id-type="pmid">17804750</pub-id></mixed-citation></ref><ref id="pone.0006412-Ebert1"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>LM</given-names></name><name><surname>Tan</surname><given-names>BS</given-names></name><name><surname>Browning</surname><given-names>J</given-names></name><name><surname>Svobodova</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>SE</given-names></name><etal/></person-group><year>2008</year><article-title>The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.</article-title><source>Cancer Res</source><volume>68</volume><fpage>3001</fpage><lpage>3009</lpage><pub-id pub-id-type="pmid">18413770</pub-id></mixed-citation></ref><ref id="pone.0006412-Walker1"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MR</given-names></name><name><surname>Kasprowicz</surname><given-names>DJ</given-names></name><name><surname>Gersuk</surname><given-names>VH</given-names></name><name><surname>Benard</surname><given-names>A</given-names></name><name><surname>Van Landeghen</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4&#x0002b;CD25- T cells.</article-title><source>J Clin Invest</source><volume>112</volume><fpage>1437</fpage><lpage>1443</lpage><pub-id pub-id-type="pmid">14597769</pub-id></mixed-citation></ref><ref id="pone.0006412-Morgan1"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>ME</given-names></name><name><surname>van Bilsen</surname><given-names>JH</given-names></name><name><surname>Bakker</surname><given-names>AM</given-names></name><name><surname>Heemskerk</surname><given-names>B</given-names></name><name><surname>Schilham</surname><given-names>MW</given-names></name><etal/></person-group><year>2005</year><article-title>Expression of FOXP3 mRNA is not confined to CD4&#x0002b;CD25&#x0002b; T regulatory cells in humans.</article-title><source>Hum Immunol</source><volume>66</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15620457</pub-id></mixed-citation></ref><ref id="pone.0006412-Roncador1"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roncador</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>PJ</given-names></name><name><surname>Maestre</surname><given-names>L</given-names></name><name><surname>Hue</surname><given-names>S</given-names></name><name><surname>Martinez-Torrecuadrada</surname><given-names>JL</given-names></name><etal/></person-group><year>2005</year><article-title>Analysis of FOXP3 protein expression in human CD4&#x0002b;CD25&#x0002b; regulatory T cells at the single-cell level.</article-title><source>Eur J Immunol</source><volume>35</volume><fpage>1681</fpage><lpage>1691</lpage><pub-id pub-id-type="pmid">15902688</pub-id></mixed-citation></ref><ref id="pone.0006412-Gavin1"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavin</surname><given-names>MA</given-names></name><name><surname>Torgerson</surname><given-names>TR</given-names></name><name><surname>Houston</surname><given-names>E</given-names></name><name><surname>DeRoos</surname><given-names>P</given-names></name><name><surname>Ho</surname><given-names>WY</given-names></name><etal/></person-group><year>2006</year><article-title>Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.</article-title><source>Proc Natl Acad Sci U S A</source><volume>103</volume><fpage>6659</fpage><lpage>6664</lpage><pub-id pub-id-type="pmid">16617117</pub-id></mixed-citation></ref><ref id="pone.0006412-Tran1"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>DQ</given-names></name><name><surname>Ramsey</surname><given-names>H</given-names></name><name><surname>Shevach</surname><given-names>EM</given-names></name></person-group><year>2007</year><article-title>Induction of FOXP3 expression in naive human CD4&#x0002b;FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.</article-title><source>Blood</source><volume>110</volume><fpage>2983</fpage><lpage>2990</lpage><pub-id pub-id-type="pmid">17644734</pub-id></mixed-citation></ref><ref id="pone.0006412-Pillai1"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>V</given-names></name><name><surname>Ortega</surname><given-names>SB</given-names></name><name><surname>Wang</surname><given-names>CK</given-names></name><name><surname>Karandikar</surname><given-names>NJ</given-names></name></person-group><year>2007</year><article-title>Transient regulatory T-cells: a state attained by all activated human T-cells.</article-title><source>Clin Immunol</source><volume>123</volume><fpage>18</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">17185041</pub-id></mixed-citation></ref><ref id="pone.0006412-Wang1"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ioan-Facsinay</surname><given-names>A</given-names></name><name><surname>van der Voort</surname><given-names>EI</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name><name><surname>Toes</surname><given-names>RE</given-names></name></person-group><year>2007</year><article-title>Transient expression of FOXP3 in human activated nonregulatory CD4&#x0002b; T cells.</article-title><source>Eur J Immunol</source><volume>37</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">17154262</pub-id></mixed-citation></ref><ref id="pone.0006412-Allan1"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>SE</given-names></name><name><surname>Crome</surname><given-names>SQ</given-names></name><name><surname>Crellin</surname><given-names>NK</given-names></name><name><surname>Passerini</surname><given-names>L</given-names></name><name><surname>Steiner</surname><given-names>TS</given-names></name><etal/></person-group><year>2007</year><article-title>Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.</article-title><source>International immunology</source><volume>19</volume><fpage>345</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">17329235</pub-id></mixed-citation></ref><ref id="pone.0006412-Imamichi1"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamichi</surname><given-names>H</given-names></name><name><surname>Sereti</surname><given-names>I</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name></person-group><year>2008</year><article-title>IL-15 acts as a potent inducer of CD4(&#x0002b;)CD25(hi) cells expressing FOXP3.</article-title><source>Eur J Immunol</source><volume>38</volume><fpage>1621</fpage><lpage>1630</lpage><pub-id pub-id-type="pmid">18493981</pub-id></mixed-citation></ref><ref id="pone.0006412-Roncarolo1"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roncarolo</surname><given-names>MG</given-names></name><name><surname>Gregori</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>Is FOXP3 a bona fide marker for human regulatory T cells?</article-title><source>Eur J Immunol</source><volume>38</volume><fpage>925</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">18395862</pub-id></mixed-citation></ref><ref id="pone.0006412-Kleinewietfeld1"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinewietfeld</surname><given-names>M</given-names></name><name><surname>Starke</surname><given-names>M</given-names></name><name><surname>Di Mitri</surname><given-names>D</given-names></name><name><surname>Borsellino</surname><given-names>G</given-names></name><name><surname>Battistini</surname><given-names>L</given-names></name><etal/></person-group><year>2009</year><article-title>CD49d provides access to &#x0201c;untouched&#x0201d; human Foxp3&#x0002b; Treg free of contaminating effector cells.</article-title><source>Blood</source><volume>113</volume><fpage>827</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">18941119</pub-id></mixed-citation></ref><ref id="pone.0006412-Banham1"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banham</surname><given-names>AH</given-names></name></person-group><year>2006</year><article-title>Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(&#x0002b;) regulatory T cells.</article-title><source>Trends Immunol</source><volume>27</volume><fpage>541</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">17045841</pub-id></mixed-citation></ref><ref id="pone.0006412-Alvaro2"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvaro</surname><given-names>T</given-names></name><name><surname>Lejeune</surname><given-names>M</given-names></name><name><surname>Salvado</surname><given-names>MT</given-names></name><name><surname>Bosch</surname><given-names>R</given-names></name><name><surname>Garcia</surname><given-names>JF</given-names></name><etal/></person-group><year>2005</year><article-title>Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.</article-title><source>Clin Cancer Res</source><volume>11</volume><fpage>1467</fpage><lpage>1473</lpage><pub-id pub-id-type="pmid">15746048</pub-id></mixed-citation></ref><ref id="pone.0006412-Badoual1"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badoual</surname><given-names>C</given-names></name><name><surname>Hans</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>J</given-names></name><name><surname>Peyrard</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>Prognostic value of tumor-infiltrating CD4&#x0002b; T-cell subpopulations in head and neck cancers.</article-title><source>Clin Cancer Res</source><volume>12</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">16428488</pub-id></mixed-citation></ref><ref id="pone.0006412-Lee1"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AM</given-names></name><name><surname>Clear</surname><given-names>AJ</given-names></name><name><surname>Calaminici</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>AJ</given-names></name><name><surname>Jordan</surname><given-names>S</given-names></name><etal/></person-group><year>2006</year><article-title>Number of CD4&#x0002b; cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.</article-title><source>J Clin Oncol</source><volume>24</volume><fpage>5052</fpage><lpage>5059</lpage><pub-id pub-id-type="pmid">17033038</pub-id></mixed-citation></ref><ref id="pone.0006412-Badoual2"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badoual</surname><given-names>C</given-names></name><name><surname>Hans</surname><given-names>S</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Brasnu</surname><given-names>D</given-names></name><name><surname>Erdman</surname><given-names>S</given-names></name><etal/></person-group><year>2009</year><article-title>Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer.</article-title><source>J Clin Oncol</source></mixed-citation></ref><ref id="pone.0006412-Hillen1"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillen</surname><given-names>F</given-names></name><name><surname>Baeten</surname><given-names>CI</given-names></name><name><surname>van de Winkel</surname><given-names>A</given-names></name><name><surname>Creytens</surname><given-names>D</given-names></name><name><surname>van der Schaft</surname><given-names>DW</given-names></name><etal/></person-group><year>2008</year><article-title>Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma.</article-title><source>Cancer Immunol Immunother</source><volume>57</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">17602225</pub-id></mixed-citation></ref><ref id="pone.0006412-Ayyoub1"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayyoub</surname><given-names>M</given-names></name><name><surname>Deknuydt</surname><given-names>F</given-names></name><name><surname>Raimbaud</surname><given-names>I</given-names></name><name><surname>Dousset</surname><given-names>C</given-names></name><name><surname>Leveque</surname><given-names>L</given-names></name><etal/></person-group><year>2009</year><article-title>Human memory FOXP3&#x0002b; Tregs secrete IL-17 ex vivo and constitutively express the TH17 lineage-specific transcription factor ROR{gamma}t.</article-title></mixed-citation></ref><ref id="pone.0006412-Voo1"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voo</surname><given-names>KS</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Santori</surname><given-names>FR</given-names></name><name><surname>Boggiano</surname><given-names>C</given-names></name><name><surname>Arima</surname><given-names>K</given-names></name><etal/></person-group><year>2009</year><article-title>Identification of IL-17-producing FOXP3&#x0002b; regulatory T cells in humans.</article-title><source>Proc Natl Acad Sci U S A</source><volume>106</volume><fpage>4793</fpage><lpage>4798</lpage><pub-id pub-id-type="pmid">19273860</pub-id></mixed-citation></ref><ref id="pone.0006412-Koenen1"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koenen</surname><given-names>HJ</given-names></name><name><surname>Smeets</surname><given-names>RL</given-names></name><name><surname>Vink</surname><given-names>PM</given-names></name><name><surname>van Rijssen</surname><given-names>E</given-names></name><name><surname>Boots</surname><given-names>AM</given-names></name><etal/></person-group><year>2008</year><article-title>Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.</article-title><source>Blood</source><volume>112</volume><fpage>2340</fpage><lpage>2352</lpage><pub-id pub-id-type="pmid">18617638</pub-id></mixed-citation></ref><ref id="pone.0006412-Bettelli1"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettelli</surname><given-names>E</given-names></name><name><surname>Carrier</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Korn</surname><given-names>T</given-names></name><name><surname>Strom</surname><given-names>TB</given-names></name><etal/></person-group><year>2006</year><article-title>Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.</article-title><source>Nature</source><volume>441</volume><fpage>235</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">16648838</pub-id></mixed-citation></ref><ref id="pone.0006412-Veldhoen1"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhoen</surname><given-names>M</given-names></name><name><surname>Hocking</surname><given-names>RJ</given-names></name><name><surname>Atkins</surname><given-names>CJ</given-names></name><name><surname>Locksley</surname><given-names>RM</given-names></name><name><surname>Stockinger</surname><given-names>B</given-names></name></person-group><year>2006</year><article-title>TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.</article-title><source>Immunity</source><volume>24</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">16473830</pub-id></mixed-citation></ref><ref id="pone.0006412-Stockinger1"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockinger</surname><given-names>B</given-names></name><name><surname>Veldhoen</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Differentiation and function of Th17 T cells.</article-title><source>Curr Opin Immunol</source><volume>19</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">17433650</pub-id></mixed-citation></ref><ref id="pone.0006412-Kato1"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Furumoto</surname><given-names>H</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Onishi</surname><given-names>Y</given-names></name><name><surname>Irahara</surname><given-names>M</given-names></name><etal/></person-group><year>2001</year><article-title>Expression of IL-17 mRNA in ovarian cancer.</article-title><source>Biochem Biophys Res Commun</source><volume>282</volume><fpage>735</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">11401524</pub-id></mixed-citation></ref><ref id="pone.0006412-Miyahara1"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyahara</surname><given-names>Y</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>G</given-names></name><name><surname>Matsuzaki</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><article-title>Generation and regulation of human CD4&#x0002b; IL-17-producing T cells in ovarian cancer.</article-title><source>Proc Natl Acad Sci U S A</source><volume>105</volume><fpage>15505</fpage><lpage>15510</lpage><pub-id pub-id-type="pmid">18832156</pub-id></mixed-citation></ref><ref id="pone.0006412-Leveque1"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leveque</surname><given-names>L</given-names></name><name><surname>Deknuydt</surname><given-names>F</given-names></name><name><surname>Bioley</surname><given-names>G</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Matsuzaki</surname><given-names>J</given-names></name><etal/></person-group><year>2009</year><article-title>Interleukin 2-mediated conversion of ovarian cancer-associated CD4&#x0002b; regulatory T cells into proinflammatory interleukin 17-producing helper T cells.</article-title><source>J Immunother</source><volume>32</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">19238008</pub-id></mixed-citation></ref><ref id="pone.0006412-Dong1"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>HP</given-names></name><name><surname>Elstrand</surname><given-names>MB</given-names></name><name><surname>Holth</surname><given-names>A</given-names></name><name><surname>Silins</surname><given-names>I</given-names></name><name><surname>Berner</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.</article-title><source>Am J Clin Pathol</source><volume>125</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">16613351</pub-id></mixed-citation></ref><ref id="pone.0006412-Hansen1"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>MH</given-names></name><name><surname>Nielsen</surname><given-names>HV</given-names></name><name><surname>Ditzel</surname><given-names>HJ</given-names></name></person-group><year>2002</year><article-title>Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells.</article-title><source>J Immunol</source><volume>169</volume><fpage>2701</fpage><lpage>2711</lpage><pub-id pub-id-type="pmid">12193744</pub-id></mixed-citation></ref><ref id="pone.0006412-Hansen2"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>MH</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name><name><surname>Ditzel</surname><given-names>HJ</given-names></name></person-group><year>2001</year><article-title>The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells.</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><fpage>12659</fpage><lpage>12664</lpage><pub-id pub-id-type="pmid">11606714</pub-id></mixed-citation></ref><ref id="pone.0006412-Schmidt1"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Bohm</surname><given-names>D</given-names></name><name><surname>von Torne</surname><given-names>C</given-names></name><name><surname>Steiner</surname><given-names>E</given-names></name><name><surname>Puhl</surname><given-names>A</given-names></name><etal/></person-group><year>2008</year><article-title>The humoral immune system has a key prognostic impact in node-negative breast cancer.</article-title><source>Cancer Res</source><volume>68</volume><fpage>5405</fpage><lpage>5413</lpage><pub-id pub-id-type="pmid">18593943</pub-id></mixed-citation></ref><ref id="pone.0006412-Wang2"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ylera</surname><given-names>F</given-names></name><name><surname>Boston</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>SG</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><etal/></person-group><year>2007</year><article-title>Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers.</article-title><source>Breast Cancer Res Treat</source><volume>104</volume><fpage>129</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">17393302</pub-id></mixed-citation></ref><ref id="pone.0006412-Coronella1"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coronella</surname><given-names>JA</given-names></name><name><surname>Spier</surname><given-names>C</given-names></name><name><surname>Welch</surname><given-names>M</given-names></name><name><surname>Trevor</surname><given-names>KT</given-names></name><name><surname>Stopeck</surname><given-names>AT</given-names></name><etal/></person-group><year>2002</year><article-title>Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.</article-title><source>J Immunol</source><volume>169</volume><fpage>1829</fpage><lpage>1836</lpage><pub-id pub-id-type="pmid">12165506</pub-id></mixed-citation></ref><ref id="pone.0006412-Kotlan1"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotlan</surname><given-names>B</given-names></name><name><surname>Simsa</surname><given-names>P</given-names></name><name><surname>Teillaud</surname><given-names>JL</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Toth</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes.</article-title><source>J Immunol</source><volume>175</volume><fpage>2278</fpage><lpage>2285</lpage><pub-id pub-id-type="pmid">16081796</pub-id></mixed-citation></ref><ref id="pone.0006412-Nzula1"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nzula</surname><given-names>S</given-names></name><name><surname>Going</surname><given-names>JJ</given-names></name><name><surname>Stott</surname><given-names>DI</given-names></name></person-group><year>2003</year><article-title>Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas.</article-title><source>Cancer Res</source><volume>63</volume><fpage>3275</fpage><lpage>3280</lpage><pub-id pub-id-type="pmid">12810659</pub-id></mixed-citation></ref><ref id="pone.0006412-KurtJones1"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurt-Jones</surname><given-names>EA</given-names></name><name><surname>Liano</surname><given-names>D</given-names></name><name><surname>HayGlass</surname><given-names>KA</given-names></name><name><surname>Benacerraf</surname><given-names>B</given-names></name><name><surname>Sy</surname><given-names>MS</given-names></name><etal/></person-group><year>1988</year><article-title>The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice.</article-title><source>J Immunol</source><volume>140</volume><fpage>3773</fpage><lpage>3778</lpage><pub-id pub-id-type="pmid">2453554</pub-id></mixed-citation></ref><ref id="pone.0006412-Yanaba1"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanaba</surname><given-names>K</given-names></name><name><surname>Bouaziz</surname><given-names>JD</given-names></name><name><surname>Matsushita</surname><given-names>T</given-names></name><name><surname>Magro</surname><given-names>CM</given-names></name><name><surname>St Clair</surname><given-names>EW</given-names></name><etal/></person-group><year>2008</year><article-title>B-lymphocyte contributions to human autoimmune disease.</article-title><source>Immunol Rev</source><volume>223</volume><fpage>284</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">18613843</pub-id></mixed-citation></ref><ref id="pone.0006412-Constant1"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constant</surname><given-names>S</given-names></name><name><surname>Schweitzer</surname><given-names>N</given-names></name><name><surname>West</surname><given-names>J</given-names></name><name><surname>Ranney</surname><given-names>P</given-names></name><name><surname>Bottomly</surname><given-names>K</given-names></name></person-group><year>1995</year><article-title>B lymphocytes can be competent antigen-presenting cells for priming CD4&#x0002b; T cells to protein antigens in vivo.</article-title><source>J Immunol</source><volume>155</volume><fpage>3734</fpage><lpage>3741</lpage><pub-id pub-id-type="pmid">7561077</pub-id></mixed-citation></ref><ref id="pone.0006412-Ron1"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ron</surname><given-names>Y</given-names></name><name><surname>De Baetselier</surname><given-names>P</given-names></name><name><surname>Gordon</surname><given-names>J</given-names></name><name><surname>Feldman</surname><given-names>M</given-names></name><name><surname>Segal</surname><given-names>S</given-names></name></person-group><year>1981</year><article-title>Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice.</article-title><source>Eur J Immunol</source><volume>11</volume><fpage>964</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">6173237</pub-id></mixed-citation></ref><ref id="pone.0006412-Ron2"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ron</surname><given-names>Y</given-names></name><name><surname>Sprent</surname><given-names>J</given-names></name></person-group><year>1987</year><article-title>T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes.</article-title><source>J Immunol</source><volume>138</volume><fpage>2848</fpage><lpage>2856</lpage><pub-id pub-id-type="pmid">2952725</pub-id></mixed-citation></ref><ref id="pone.0006412-Janeway1"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janeway</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Ron</surname><given-names>J</given-names></name><name><surname>Katz</surname><given-names>ME</given-names></name></person-group><year>1987</year><article-title>The B cell is the initiating antigen-presenting cell in peripheral lymph nodes.</article-title><source>J Immunol</source><volume>138</volume><fpage>1051</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">3100626</pub-id></mixed-citation></ref><ref id="pone.0006412-Liu2"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Ramarathinam</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Huszar</surname><given-names>D</given-names></name><etal/></person-group><year>1995</year><article-title>Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response.</article-title><source>Int Immunol</source><volume>7</volume><fpage>1353</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">7495742</pub-id></mixed-citation></ref><ref id="pone.0006412-Linton1"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linton</surname><given-names>PJ</given-names></name><name><surname>Harbertson</surname><given-names>J</given-names></name><name><surname>Bradley</surname><given-names>LM</given-names></name></person-group><year>2000</year><article-title>A critical role for B cells in the development of memory CD4 cells.</article-title><source>J Immunol</source><volume>165</volume><fpage>5558</fpage><lpage>5565</lpage><pub-id pub-id-type="pmid">11067910</pub-id></mixed-citation></ref><ref id="pone.0006412-Crawford1"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>A</given-names></name><name><surname>Macleod</surname><given-names>M</given-names></name><name><surname>Schumacher</surname><given-names>T</given-names></name><name><surname>Corlett</surname><given-names>L</given-names></name><name><surname>Gray</surname><given-names>D</given-names></name></person-group><year>2006</year><article-title>Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells.</article-title><source>J Immunol</source><volume>176</volume><fpage>3498</fpage><lpage>3506</lpage><pub-id pub-id-type="pmid">16517718</pub-id></mixed-citation></ref><ref id="pone.0006412-Shen1"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Whitmire</surname><given-names>JK</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Shedlock</surname><given-names>DJ</given-names></name><name><surname>Kaech</surname><given-names>SM</given-names></name><etal/></person-group><year>2003</year><article-title>A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes.</article-title><source>J Immunol</source><volume>170</volume><fpage>1443</fpage><lpage>1451</lpage><pub-id pub-id-type="pmid">12538706</pub-id></mixed-citation></ref><ref id="pone.0006412-Ronchese1"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronchese</surname><given-names>F</given-names></name><name><surname>Hausmann</surname><given-names>B</given-names></name></person-group><year>1993</year><article-title>B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes.</article-title><source>J Exp Med</source><volume>177</volume><fpage>679</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">8436906</pub-id></mixed-citation></ref><ref id="pone.0006412-Tamiolakis1"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamiolakis</surname><given-names>D</given-names></name><name><surname>Simopoulos</surname><given-names>C</given-names></name><name><surname>Cheva</surname><given-names>A</given-names></name><name><surname>Lambropoulou</surname><given-names>M</given-names></name><name><surname>Kotini</surname><given-names>A</given-names></name><etal/></person-group><year>2002</year><article-title>Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast.</article-title><source>Eur J Gynaecol Oncol</source><volume>23</volume><fpage>433</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">12440819</pub-id></mixed-citation></ref><ref id="pone.0006412-AlShibli1"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Shibli</surname><given-names>KI</given-names></name><name><surname>Donnem</surname><given-names>T</given-names></name><name><surname>Al-Saad</surname><given-names>S</given-names></name><name><surname>Persson</surname><given-names>M</given-names></name><name><surname>Bremnes</surname><given-names>RM</given-names></name><etal/></person-group><year>2008</year><article-title>Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>5220</fpage><lpage>5227</lpage><pub-id pub-id-type="pmid">18698040</pub-id></mixed-citation></ref><ref id="pone.0006412-Nedergaard1"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nedergaard</surname><given-names>BS</given-names></name><name><surname>Ladekarl</surname><given-names>M</given-names></name><name><surname>Nyengaard</surname><given-names>JR</given-names></name><name><surname>Nielsen</surname><given-names>K</given-names></name></person-group><year>2008</year><article-title>A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years.</article-title><source>Gynecol Oncol</source><volume>108</volume><fpage>106</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">17945335</pub-id></mixed-citation></ref><ref id="pone.0006412-Bingle1"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bingle</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>NJ</given-names></name><name><surname>Lewis</surname><given-names>CE</given-names></name></person-group><year>2002</year><article-title>The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.</article-title><source>J Pathol</source><volume>196</volume><fpage>254</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">11857487</pub-id></mixed-citation></ref><ref id="pone.0006412-Sica1"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Larghi</surname><given-names>P</given-names></name><name><surname>Mancino</surname><given-names>A</given-names></name><name><surname>Rubino</surname><given-names>L</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><etal/></person-group><year>2008</year><article-title>Macrophage polarization in tumour progression.</article-title><source>Semin Cancer Biol</source><volume>18</volume><fpage>349</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">18467122</pub-id></mixed-citation></ref><ref id="pone.0006412-Gottfried1"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottfried</surname><given-names>E</given-names></name><name><surname>Kunz-Schughart</surname><given-names>LA</given-names></name><name><surname>Weber</surname><given-names>A</given-names></name><name><surname>Rehli</surname><given-names>M</given-names></name><name><surname>Peuker</surname><given-names>A</given-names></name><etal/></person-group><year>2008</year><article-title>Expression of CD68 in non-myeloid cell types.</article-title><source>Scand J Immunol</source><volume>67</volume><fpage>453</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">18405323</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The study was funded by grants from the British Columbia Cancer Foundation, Vancouver General Hospital Foundation, and U.S. Dept. of Defense (OC000018). None of the sponsors had any role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.</p></fn></fn-group></back></article>